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CHAPTER 1 
INTRODUCTICœj ON THE TREATMENT OF ACROMEGALY 

Patients with acromegaly have a reduced life expectancy due to cardio-
vascular, cerebrovascular and respiratory disease [1,2]. Since morta-
lity rates are higher for untreated than for treated patients, all pa-
tients with active acromegaly should be treated. Therapy is directed to 
normalization of GH secretion and reduction of pituitary tumour mass. 
Normal pituitary function should be preserved as long as possible. 
1.1 SURGERY AND RADIOTHERAPY 
The primary approach of acromegaly still is surgical [3]. Transsphenoi-
dal resection of the pituitary adenoma is the method of choice in the 
great majority of cases. Excluded are large tumours with extensive su-
prasellar or parasellar extension. These tumours must be approached via 
craniotomy. Cure rates range from 78 to 97% for microadenomata (diame-
ter less than 10 mm) and from 33 to 90% for macroadenomata [4-7]. It is 
of note that cure rates, apart from size, location, direction of 
growth, invasiveness, resectability of tumours and skill of the surge-
on, depend on the criterion used for "cure". The cut-off value for nor-
malcy of GH has decreased over the years and differs among reported 
series, which is probably induced by the growing knowledge on size he-
terogeneity and circulating binding proteins for GH [8], making compa-
risons difficult. Complications of surgery include hypopituitarism (5-
15%), cerebrospinal fluid rhinorrhea (1-5%), meningitis (0.5-2.5%) and 
permanent diabetes insipidus (0.5-1%)[4-7]. 
Radiation therapy should be considered adjunctive rather than pri-
mary for acromegaly and is appropriate in patients not cured by surgi-
cal treatment. Radiotherapy is not recommended as a first line treat-
ment, because improvement is slow in onset and may extend over five to 
fifteen years [9-11], leaving the acromegalic state initially unchanged 
in the mean time demanding medical therapy. The rate of decline of GH 
levels may be somewhat faster with heavy particle therapy than with 
conventional radiotherapy. Using the former technique GH levels less 
than 5 ng/ml are achieved in 59% of patients five years after treatment 
[12]. Side effects of both modalities are hypopituitarism, being less 
frequent after heavy particle therapy: 10-30% [10,11,13] compared to up 
to 50% [9], while damage to optic and oculomotor nerves is an addition-
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al risk using the latter technique [3]. 
Medical therapy with dopamine agonists or somatostatin analogues, 
although not always effective, is recommended for second or third line 
treatment after surgery and radiotherapy, awaiting the effect of the 
latter treatment modality. When surgery has not been successful and 
radiotherapy is not considered, long-term medical therapy can also be 
the treatment of choice. Furthermore, it might be used preoperatively 
to relieve symptoms of acromegaly or to achieve tumour size reduction 
(see chapter 4)[14]. 
1.2 MEDICAL TREATMENT 
1.2.1 Bromocriptine 
The paradoxical reduction of growth hormone levels by L-DOPA in more 
than 50% of acromegalic patients [15] has led to the therapeutical use 
of dopamine agonists. One of them, bromocriptine, is effective in lo-
wering GH levels [15-23]. Generally large doses are required (10-20 mg) 
and not all patients can tolerate these doses because of gastrointes-
tinal side-effects or postural hypotension. Plasma GH reduction to the 
normal range is limited to about 30% of the patients. Dosages above 20 
mg per day do not seem to lead to better results with respect to lower-
ing GH levels [6,8]. Remarkably in some patients a discrepancy has been 
noted between biochemical and clinical improvement [21,22]. Unlike pro-
lactinomas, GH-producing adenomata do not usually shrink in response to 
bromocriptine [24]. For all these reasons bromocriptine is not the 
first choice treatment for acromegaly. 
1.2.2 Somatostatin 
Native somatostatin (Somatotropin Release Inhibiting Hormone, SRIH) is 
a tetradecapeptide that inhibits GH secretion from anterior pituitary 
cells [25,26], but also the secretion of numerous hormones of various 
other organs [26]. Other mammalian somatostatins were shown to have 
identical amino acid sequences. SRlH-like peptides from early vertebra-
tes are also closely similar [26], which implies that this peptide is 
phylogenetically important in vertebrate physiology. 
GH release from human pituitary GH-secreting adenoma cells in cul-
ture is inhibited by SRIH [27,28]. This inhibitory effect is probably 
mediated by specific SRIH-receptors on adenoma cell membranes, since 
high affinity and specific SRIH-receptors have been identified in human 
GH-secreting adenomas [29-31] with evidence for different tumor sub-
classes [32]. 
In acromegalic patients GH secretion also is inhibited by infusion 
of the natural somatostatin [33-41], but is followed by a rebound in-
crease in plasma GH levels after termination of the SRIH-infusion 
[37,41,42]. Interestingly, evidence was found for the existence of two 
different subgroups of acromegalics characterized by different sensiti-
vities to SRIH [37,38]. Chronic therapy with the native peptide was not 
attempted because of the rebound GH secretion and the necessity of con-
tinuous infusion therapy due to the short half-life of SRIH, i.e. 1-3 
min [42]. 
1.2.3 Octreotide 
1. Introduction 
After the initial discovery of native SRIH it took many years to obtain 
a clinically useful analogue. At first the aim was to find the "minimal 
essential amino-acid sequence" of SRIH in the course of which a number 
of peptide analogues of reduced size were synthesized. This sequence 
proved to be Phe7 to Thr10 [43-46]. Additional structural elements of 
the natural tetradecapeptide were stepwise incorporated in this minimal 
essential sequence. The tetrapeptide sequence Phe7 to Thr10 was first 
conformationally stabilized by means of cyclization with a cystine 
bridge. Then, by changing the amino-terminal and the carboxy-terminal 
end, the octapeptide SMS 201-995 (SMS, octreotide, SandostatinR) was 
selected for further development (Fig.1)[47], because in an animal mo-
del it proved to be at least 20 times more active than SRIH, longer 
acting and more selective in inhibiting the secretion of growth hormone 
than that of insulin [48]. 
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SRIH 
Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys 
SMS 201-995 
D Phe-Cys-Phe-D Trp-Lys-Thr-Cys-Thrlol) 
Fig.l. Biochemical structures of native somatostatin (SRIH) and the 
octapeptide analogue SMS 201-995 
2. Pharmacokinetics 
Although oral administration of high doses of SMS (4-8 mg) together 
with 50 g glucose (to improve absorption) in man results in therapeutic 
levels in the circulation [49], this route and required dose of admini­
stration is not attractive because it is impractical and expensive com­
pared to the dose used with subcutaneous (sc) administration. 
After sc injection, octreotide is absorbed rapidly and completely 
from the injection site. Following single injections of 50 or 100 цд in 
man, plasma peak levels at 30-60 min are 1.9 and 2.7 ng/ml respectively 
[50], with an elimination half-life (ti/z) of 90-113 min for both doses 
[50,51]. Relative to an equivalent intravenous (i.v.) dose, the bio­
availability of a subcutaneous dose was estimated to be 80-135% and the 
volume of distribution 13.6 L. 
About 65% of the drug is bound in the plasma in a concentration in­
dependent manner. Binding is mainly to lipoprotein and, to a lesser 
extent, to albumin. 
The plasma concentration and the area under the plasma-concentra-
14 
tion-versus-time curve (AUG) increased dose-dependently after i.v. as 
well as after sc administration, pointing to linear pharmacokinetics 
for SMS [51]. At daily doses of 600 ug as compared to 150 \ig, clearance 
was reduced by about 66% suggesting non-linear kinetics. When adminis­
tered se or iv to bile-duct-cannulated rats, 50% respectively 73% of 
the given dose are excreted in bile within 8 hours, mainly as unchanged 
drug [47]. About 20 to 25% of the administered dose appears in the uri­
ne, again unmetabolized. In intact animals, almost no unchanged drug 
could be recovered from the faeces. Thus in the rat SMS is mainly ex­
creted via the bile and is then broken down in its further passage 
through the gastrointestinal tract [47]. In man about 32% of the dose 
administered is excreted unchanged into the urine. In patients with 
severe renal failure requiring dialysis, clearance was reduced to about 
half that found in normal subjects [52]. The effect of hepatic diseases 
on the disposition of octreotide is unknown. The hepatic extraction of 
SMS was estimated to be between 30 and 40% in healthy volunteers, poin­
ting to hepatic metabolism of the drug [51]. However, infusion of na­
tive SRIH in patients with hepatic disease or normal subjects did not 
result in significant differences in either clearance or ti/ 2 [42] in 
spite of the observation that a transhepatic gradient exists in the dog 
[53] and the rat [54]. Apart from hepatic metabolism and renal excre­
tion, analogous to SRIH [55,56], degradative enzymes in blood and tis­
sue may also play an important role in octreotide catabolism. 
3. Studies in normal volunteers 
In normal volunteers spontaneous daytime peaks of GH secretion are de­
layed following sc injection of 50 pg SMS twice daily, but nocturnal 
and total GH secretion are not affected during this regime [57]. Sleep-
induced GH secretion has been reported to be abolished following a sin­
gle injection of 100 \ig of SMS immediately before sleep [58]. A 50 цд 
injection of octreotide also suppresses arginine-induced GH release 
[58]. Continuous iv SMS administration results in a profound and selec­
tive suppression of the GH response to hypoglycaemia without affecting 
the ACTH or Cortisol responses [59]. In the same study the LH response 
to LHRH was blunted but the FSH response unaffected. 
In acute studies SMS has been reported to suppress TRH-stimulated TSH 
secretion [57,59]. The nocturnal rise in thyrotropin is also abolished 
15 
by SMS, thyroid function, however, is unaffected [57]. 
Basal insulin levels are suppressed following SMS and the response to 
meals is inhibited [60]. In normal individuals the analogue also inhi­
bits glucagon secretion for up to 6 hours. These phenomena together 
cause glucose intolerance following meals, while fasting glucose levels 
remain unchanged [57,60]. Several regulatory gut peptide hormones are 
also suppressed following injection of SMS: cholecystokinin, gastrin, 
gastric inhibitory peptide, secretin, neurotensin, pancreatic polypep­
tide and motilin [60,61]. Furthermore, the analogue causes inhibition 
of exocrine pancreatic secretion in short-lasting studies [61-63]. Gas­
tric emptying is accelerated by a single sc injection of 50 цд SMS, 
whereas mouth-to-caecum transit time is markedly prolonged [64]. 
4. Treatment of acromegaly 
In acute studies marked suppression of growth hormone release was ob­
served in most patients, using sc administration of 50 to 100 цд SMS 
twice or thrice daily. This effect was maximal after 2 h and continued 
for 6 to 8 h after each dose [65-70]. Excessive rebound hypersecretion 
after withdrawal of the octapeptide was not reported in the majority of 
studies, although Barnard et al. recorded this phenomenon in two out of 
five patients after 2 weeks of treatment [71]. They suggested that in 
the short term SMS inhibited secretion of growth hormone rather than 
synthesis. 
Several studies have reported on long term use of octreotide therapy 
in acromegaly [66,69-83, see for reviews: 84,85]. There is a considera­
ble interindividual variation between acromegalic patients in the sen­
sitivity of GH secretion to the analog: normalization of mean GH levels 
was reached in some patients on a dose scheme of 50 цд or 100 цд SMS 
b.i.d. [72,74], whereas other patients needed higher doses of even 1000 
\ig t.i.d. [77]. Normal nadir GH levels are reached in about 70% of the 
patients during long-term intermittent sc treatment with octreotide. 
Only exceptionally GH remained unaffected. During long-term treatment 
no endogenous antibody formation could be detected (confer chapter 
3.3). 
Currently it is still unknown how often and in what dose SMS should be 
administered to acromegalic patients. The recommended dosage schedules 
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for intermittent sc therapy vary remarkably widely from 50 \ig twice 
daily to three times 500 цд daily. Only a few dose response studies 
have been performed with divergent results (confer chapter 2) 
[77,83,86]. 
In determining the effect of medical therapy of acromegaly, measure­
ment of Insulin Like Growth Factor I (IGF-I) levels has been suggested 
to replace multiple measurements of plasma GH concentrations during the 
day, since a close correlation was found between these two parameters 
[66,72,74,87,88]. Sometimes, however, specificity of IGF-I determina­
tions is lacking [89,90]. Furthermore, sustained reduction of growth 
hormone concentrations is not necessary to achieve significant reduc­
tion in IGF-I concentrations [72]. No consensus exists, how to deter­
mine cure biochemically, especially during the intermittent se admini­
stration of SMS compared with continuous treatment. Apart from IGF-I 
levels, measuring plasma GH levels at fixed intervals during the day, 
determining the integrated secretion throughout the day and the nadir 
GH value, GH suppressibility by an oral glucose loading may also be a 
useful tool (confer chapter 3.2) [91]. 
Besides biochemical amelioration, also rapid clinical improvement oc­
curs during the first weeks of treatment [65,75]. For instance headache 
may disappear as soon as two minutes after injection of the somatosta­
tin analog, as has clearly been demonstrated in a placebo controlled 
double blind study [92]. The effect of octreotide on the size of the 
pituitary tumour will be discussed in chapter 4. 
Continuous subcutaneous administration of SMS has also been succes-
fully applied in the treatment of acromegaly [93-96], resulting in a 
more profound [93] and stable [93,96] suppression of GH secretion in 
many patients as compared to the intermittent administration. Doses 
used were between 100 and 600 цд per day. The definite place of this 
route of administration remains still unclear due to the small number 
of well designed comparative studies on this subject. 
Besides the sc route, orally administered octreotide is also poten­
tially valuable in the treatment of acromegaly. Doses of 4-8 mg in a 50 
g glucose solution three times daily lowered mean 24 h GH concentra­
tions by over 50% [49]. However, as stated before, the 40 to 80 times 
higher doses needed as compared to the sc administration make the the­
rapy with this analogue until now unacceptably impractical. 
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The efficacy of SMS in the treatment of acromegalic patients seems 
better than reached with bromocriptine [73,97], but comparative studies 
of chronic treatment with both drugs are still lacking. At least in a 
minority of acromegalic patients combination therapy proved to be su-
perior [97]. The GH response to SMS did not differ between patients 
with pure GH secreting tumors and the patients with mixed GH/prolactin 
containing tumours. In some of the latter patients normalization of 
plasma prolactin levels did occur in response to SMS [98], possibly 
related to the presence of GH and prolactin within the same tumour 
cells, which might have adopted to a certain extent the usual characte-
ristics of the tumorous GH-secreting cells with regard to their sensi-
tivity to somatostatin. 
5. side effects 
Octreotide has been generally well tolerated whatever route or schedule 
of administration used. Most patients note some pain at the injection 
site and abdominal cramping, flatulence and loose stools during the 
first days of therapy, but these side effects largely resolve with con-
tinued therapy. Exceptionally, therapy has to be discontinued due to 
these side effects. Some of these adverse events of octreotide can be 
predicted from signs and symptoms occurring in patients with SRIH-pro-
ducing tumours [99], the most important being steatorrhea, diabetes 
mellitus and cholelithiasis. Daily stool fat showed an average increase 
from 2.6 to 6 g without clinical evidence of malabsorption [66,67,72], 
whereas clinical steatorrhea and acute weight loss occurred in only 3 
out of 54 patients with acromegaly receiving daily doses of 100-300 \ig 
SMS for more than 4 weeks [67]. Octreotide abolishes postprandial PP 
secretion and gallbladder contraction during long-term treatment in 
acromegaly, despite a blunted but still significant CCK release. Exo-
crine pancreatic function after long-term SMS treatment, however, is 
similar to that after placebo and remains superior to that in healthy 
volunteers (confer chapter 5.2). 
Well documented gallstone formation during long-term therapy with the 
SRIH-analogue has been reported in only a few patients [74,94,95]. Also 
accumulation of thickened bile containing echodense particles has been 
published [84]. This latter study contained one patient who developed 
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episodes of biliary colic necessitating cholecystectomy. No prospec­
tive, randomized study on this subject has been performed until now. 
Long-term intermittent subcutaneous therapy in our 16 patients did not 
result in cholelithiasis, although we showed that postprandial gall­
bladder contraction was abolished (see chapter 5.1). Although it will 
be difficult to prove the existence of a higher incidence of gallblad­
der or biliary pathology during SMS treatment, the reported incidence 
by Tauber et al. of 2 out of 16 patients during continuous sc treatment 
[95] to our opinion is suspect for a causative role of the somatostatin 
analogue. 
In acromegalic patients oral hypoglycemic drug therapy had to be initi­
ated in 2 out of 34 patients in whom type II diabetes mellitus had de­
veloped during SMS therapy [100,101]. However, in most acromegalic pa­
tients only a mild glucose intolerance develops with normal fasting 
glucose levels [72], comparable to the effect in normal man [57,60]. 
Although SMS has been reported to suppress TRH-stimulated TSH secretion 
[57,59] in normal volunteers, thyroid function in normal man as well as 
in patients on long-term octreotide therapy is unaffected. 
No desensitization has been observed so far in acromegalic patients 
during intermittent sc treatment with 200-300 \ig SMS per day for more 
than 3 yr, both with respect to GH and insulin release [85]. 
6. Other indications for the use of SRIF-analogs 
Octreotide has been used in the symptomatic and palliative treatment of 
endocrine tumours of the gastrointestinal system [see for review 84], 
e.g. carcinoid tumours [102,103], insulinomas [104-107], glucagonomas 
[108], gastrinomas [103,109] and VIPomas [109,110]. Although inciden­
tally some tumour regression seems to occur, this treatment must be 
considered symptomatic only. An important advantage though, compared 
with cytotoxic chemotherapy is its lack of serious side effects. Be­
cause these tumours are rare and have differing natural histories, no 
controlled trials have been done. In the reported patients there has 
been no standardization of previous therapy, indications for therapy, 
doses of SMS used, or frequency or quality of follow-up. Therefore, no 
strict recommendation can be given on the dose to be used. Generally, 
therapy is started with 50 ug b.i.d. sc increasing up to 1500 цд per 
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day. Interestingly, in contrast to the long-term treatment of GH pro-
ducing pituitary adenomas, development of resistance to the analog has 
been described in non-acromegalic patients probably due to down-regula-
tion of somatostatin receptors [102]. 
Several non-oncological gastroenterological applications have been 
proposed for octreotide. Symptoms of the dumping syndrome have been 
shown to be improved by SMS in short-lasting studies, probably by slow-
ing gastrointestinal transit [111,112]. Controlled studies on the long-
term effect of this treatment are still lacking. 
Although promising reports have been published on the potential role of 
somatostatin analogs in the treatment of high output secretory diar-
rhea, and intestinal and pancreatic fistulas [113-118], no conclusive 
recommendations can be made since the results of large scale prospec-
tive trials are not available yet. 
The analogue octreotide, like SRIH [25,119], also shows beneficial 
effects in patients with insulin-dependent diabetes mellitus [120,121], 
probably by lowering post-prandial blood glucose peaks via its delaying 
effect on gastrointestinal absorption and its inhibitory effect on the 
secretion of GH and glucagon [122,123]. GH and somatomedin levels drop-
ped and insulin requirements were reduced by a mean of 28% [121]. Its 
clinical applicability on the long run has to be determined yet. 
Somatostatin receptor activity has been demonstrated in several tu-
mours, e.g. breast carcinoma [124], astrocytoma and meningioma 
[125,126] and scintigraphic imaging with a radioiodinated analogue of 
SMS can localize somatostatin receptor positive primary and metastatic 
tumours in vivo [127]. Octreotide has been shown to directly inhibit 
the proliferation of the human breast cancer cell line MCF-7 [124]. 
Surprisingly, no antiproliferative activity could be demonstrated a-
gainst meningioma cell growth in vitro [128] although this tumour is 
known to present SRIF-receptor activity [126] and inhibition of growth 
of a meningioma in vivo has been reported [129]. In rat transplanted 
chondrosarcoma also inhibition of tumor growth was induced by SMS 
[130]. This effect and probably all anti-tumour activity of somatosta-
tin analogues might be mediated by the inhibition of GH-release, pro-
lactin, growth factors and insulin rather than a direct effect on soma-
tostatin receptors [see for review 131,132]. 
Apart from possible applications of octreotide mentioned above, dozens 
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of others have been suggested, of which we only mention the interesting 
effect on postprandial hypotension [133-136]. 
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ABSTRACT 
The recommended dosage schedules for intermittent subcutaneous therapy 
with the somatostatin analogue octreotide in acromegaly vary widely, 
from 100 to 1500 цд daily. As acute administration of octreotide has 
been shown to predict its long-term response, we performed a single-
dose response study in five patients with active acromegaly using doses 
of 25, 50, 100, 200 and 400 \ig octreotide as well as a placebo injec­
tion. 
Plasma GH of two patients did not normalize after any of the injec­
tions, but nadir plasma GH overall gradually decreased as doses were 
increased from 25 to 400 цд. The 400 цд octreotide dose was superior 
with regard to the duration of plasma GH suppression to below 5 цд/1 or 
25% of the basal GH level, the mean GH as a percentage of the basal 
level over the first 4 and 8 h and the integrated reduction of plasma 
GH during the first 4 and 8 h. The postprandial integrated insulin se­
cretion during the first 3 hrs after injection of the octapeptide was 
significantly lower after 50, 100 and 400 цд than after the placebo in­
jection. The mean plasma glucose as a percentage of the basal level 
during the first 8 h was significantly higher after octreotide after 
the 200 and 400 цд injections. Minor adverse events were seen in two 
patients after injection of 200 and 400 цд octreotide. 
Within the limitations of this single-dose response study it was 
concluded that injection of 400 цд octreotide yields the best results 
with regard to suppression of GH secretion, while the 50, 100 and 200 
цд doses are superior to 25 цд, but do not differ from each other. 
INTRODUCTION 
The somatostatin analogue octreotide (SMS 201-995) is widely used in 
the treatment of acromegaly and gastrointestinal tumours. In the vast 
majority of published reports high clinical and biochemical efficacy in 
acromegaly has been documented [1-14]. The recommended dosage schedules 
for intermittent subcutaneous (sc) therapy vary remarkably widely from 
50 цд twice daily to three times 500 цд each day. Only a few dose res­
ponse studies have been performed with divergent results [10,15]. 
33 
As a simple acute administration of octreotide has been shown to 
predict the response after long-term treatment [4,7,16], the aim of our 
study was to compare the effects of single injections of different do­
ses of octreotide currently used in clinical practice on plasma growth 
hormone (GH), insulin and glucose in patients with acromegaly. 
PATIENTS AND METHODS 
Five patients with active acromegaly (aged 31-67 years; 1 man, 4 women) 
participated in the study after giving informed consent. Inclusion cri­
teria were the classical clinical findings of acromegaly and an eleva­
ted fasting concentration of plasma growth hormone that was not comple­
tely suppressed by 100 g oral glucose loading. Clinical data on the pa­
tients are given in Table 1. One of the subjects (no.4) had diabetes 
mellitus, treated with a diet and oral antidiabetic therapy. Four of 
the patients had been treated before with subcutaneous (sc) injections 
of octreotide 2-3 times daily for 5-31 months. The mean daily dose of 
the analogue was 200 цд, range 100-300 цд. Octreotide therapy was with­
held for at least one week prior to the study. Bromocriptine medication 
had been stopped 5-32 months before studying octreotide dose-response 
relationship. The protocol was approved by the ethics committee of the 
Nijmegen University Hospital. 
The patients were hospitalized and ingested their meals at exactly 
08.30 h, 12.00 h and 17.00 h. The breakfast on the test days was stan­
dardized (17 g protein ,20 g fat and 51 g carbohydrates). Major exer­
cise was not allowed. 
In a single blind study, on each test day either placebo (1 ml of sa­
line 0.9%) or a single dose of 25, 50, 100, 200 or 400 \ig of octreotide 
(Sandoz Ltd; Basle, Switzerland) was administered sc at 08.30 h. (t= 
0). This pattern of increasing doses in the first patient was alterna­
ted with decreasing doses in the next patient and so on. There was an 
interval of at least 48 h between two injections. No additional bromo­
criptine therapy was applied in any patient. Blood for GH, insulin, and 
glucose measurements was drawn through an indwelling venous catheter 30 
min before and 0, 1,2, 3 , 4 , 6 , 8 , 10 and 12 hours after the injec­
tion. Any adverse events were recorded. 
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Table 1. Patient Data 
Patient Age Sex Basal Daily Dose Duration 
no. (years) plasma GH octreotide of octreotide 
(Mg/L) (цд) treatment (months) 
Previous Therapy1 
46 
67 
31 
61 
36 
F 
F 
F 
F 
M 
26 
14 
35 
2Θ 
26 
-
100 
200 
300 
200 
0 
31 
14 
5 
9 
Br R 
Br AR 
TSS, TFS, Irr, 
Br R 
TFS, Br R 
Br R 
1
 TSS: Transsphencidal surgery. TFS: Transfrcntal surgery. Irr: External irradiation. Br R: Bro­
mocriptine resistant. Br AR: Adverse reactions on bromocriptine. 
Plasma GH and plasma insulin levels were determined using sensitive 
and specific radioimmunoassays as described before [17,8]. Integrated 
plasma GH and insulin were determined by calculating the area under the 
plasma concentration-time curve after subtraction of the basal prepran-
dial value (t= 0). Results were expressed as the mean + standard error 
of the mean (SEM). Statistical analysis was performed by means of Stu­
dent's t-test for paired data (p) and of Friedman's two-way analysis of 
variance (P)[18]. 
RESULTS 
Effect of octreotide on plasma GH levels (Table 2;Fig.l,2 and 3) 
Any dose of octreotide, but not the placebo, caused a fast and statis­
tically significant decrease of the plasma GH concentration (P<0.05-
0.005). Nadir GH was in the normal range (<5 цд/1) after injection of 
each of the doses in one patient (no.4), after doses exceeding 25 цд in 
one (no.2), and after doses exceeding 50 цд in another one (no.3). 
Plasma GH of two patients (nos 1 and 5) did not normalize after any of 
the octreotide injections. Nadir plasma GH gradually decreased on in­
creasing doses from 25 to 400 цд octreotide (P<0.05). A statistically 
significant difference, however, was observed only when the dose of 25 
\ig was compared with the three higher doses of 50, 200 and 400 цд oc­
treotide (p<0.05). 
The duration of plasma GH suppression to below 5 цд/1 or 25% of the 
basal GH concentration gradually increased as the dose of the octapep-
tide was raised from 25 to 400 \ig (P<0.05). By the latter criterion the 
highest dose, of 400 цд, was superior to the 25, 100 and 200 \ig injec­
tions (p<0.05). 
It is to be noted that the mean plasma GH expressed as a percentage 
of the basal value (mean GH%) over 12 hrs was significantly lower than 
the placebo value only at doses of 200 and 400 цд octreotide (p<0.05, 
data not shown). Again, the dose of 400 цд resulted in a significantly 
lower mean GH% than those of 100 or 200 цд (p<0.05). When only the 
first 4 or 8 hrs (Table 2) of the test day were considered, at all do­
ses of the somatostatin analogue the mean GH% was lower than the plac-
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ebo value, the 400 ug dose again being the most effective. 
Naturally, the integrated reduction of plasma GH expressed as a per­
centage of the basal level (AUG GH%) showed similar results: calculated 
over 12 hrs all doses exceeding 25 цд octreotide resulted in a signifi­
cantly more pronounced integrated GH reduction than placebo injection 
(p<0.05, data not shown), the 400 цд dose being more effective than the 
200 цд dose (p<0.05). It is to be noted that over the first 4 (data not 
shown) and 8 hours (Table 2) the 50, 100 and 200 цд octreotide doses 
decreased GH% to the same extent. In this respect only the dose of 400 
цд was significantly superior to any of the lower doses. The advantage 
of increasing doses seems to level of at doses above 50 цд (Fig.3). 
Effect of octreotide on plasma insulin levels (Table 3;Fig.l) 
After placebo an overt postprandial insulin secretion was recorded af­
ter each of the three meals (mean peak levels as percentages of basal 
level 311 + 69%, 696 + 311% and 603 + 270% respectively (p<0.05). The 
postprandial insulin secretion evoked by the standard breakfast in the 
placebo study was completely suppressed by octreotide. The postprandial 
insulin peak after the standard breakfast was reversed by all doses of 
octreotide (Fig.l). After the second and third meal, however, again a 
rise in mean plasma insulin concentrations could be noted. The 50 цд 
injection resulted after the standard breakfast in a statistically sig­
nificant decrease of plasma insulin to 46.1 + 13.8% of the basal level; 
only a tendency to decrease was recorded after injection of 25, 100 and 
400 цд (0.05<p<0.10), but not after 200 цд octreotide (p=0.13). 
After the 50, 100 and 400 цд octreotide doses the integrated insulin 
secretion (AUG insulin) during the first 3-hr interval between the 
standard breakfast and lunch was significantly lower than that after 
placebo (p<0.05). For the different doses the AUG insulin over 8 and 12 
hrs was comparable to that after placebo (p>0.10). 
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7 . ol basal plasma Glucose 
175 
15СЧ 
125-
ιοο· 
75 
7. of basal plasma Insulin 
600 
¿00-
π г-
200 
40 
20-
7o of basal plasma Growth Hormone 
80 
60H 
SMS a-^-A<r-' 
plac 
10 12 
time (hrs) 
1 Mean 12 hr plasma grovrth hormone, insulin and glucose profiles 
expressed as percentage of the basal level after injection of 
saline placebo (Plac) and after subcutaneous injection of dif­
ferent doses of octreotide (SMS) in five patients with acromega­
ly. ^ indicates meals. For clarity's sake the SEMs have been 
omitted. 
Table 2. Plasma Growth Hormone Results ci 
Dose Nadir GH Œ <5 цд/Ь ŒI <25%1 Mean GH%2 AUC GH%3 
octreotide (цд/і) time (hrs) time (hrs) 0-8 hrs 0- hrs 
placebo 
25 μς 
50 цд 
100 μς 
200 \ід 
40С цд 
17.9 + 4.3 
6.1 ¿ 1.2 
4.9 + 1.0 
4.6 + 1.5 
3.7 + 1.0 
3.5 + 1.1 
(#)л 
(*#) 
(*#) 
0.0 
0.8 + 0.8 
2.6 + 2.4 
2.8 + 1.3 
3.6 + 1.5 
6.2 + 2.6 
0.0 
0.6 + 0.6 
3.4 + 2.4 
3.4 + 1.9 
4.0 + 1.8 
6.8 + 2.3 (*#•») 
95.8 + 7.4 
60.0 + 7.3 
36.4 + 8.3 
39.1 + 10.4 
27.9 + 7.4 
21.6 + 7.4 ι 
(*! 
(*#) 
<*#) 
(*#) 
[*#•») 
37 + 55 
290 + 60 
480 + 61 
462 + 78 
545 + 55 
592 + 56 
(*) 
(*#) 
(*#) 
(*#) 
(*#•») 
1
 Period that plasma GH was lower than 25% cf baseline value 
2
 Mean cf plasma GH in percentage cf baseline value 
3
 Area under the curve cf plasma GH expressed as a percentage cf the basal value 
л
 p<0.05 vs placebo (*!, 25 \iq <#) , 50 цд (&), 100 цд (•) , 200 цд octreotide (»! 
Nadir plasma GH (/jg/l) 
10 
plac 25 50 100 200 ¿8o 
Octreotide dose (/ug) 
2 Individuai nadir GH values after injection of saline placebo 
(plac) and after subcutaneous injection of different doses of 
octreotide in five patients with acromegaly. The dotted line 
illustrates the generally held cut-off value for normalcy. 
Integrated reduction of plasma GH (% 8 h) 
600-
500 
400 
300 
100 200 300 400 
Octreotide dose (yug) 
3 Mean 8 hrs integrated reduction of plasma growth hormone expres-
sed as percentage of the basal plasma growth hormone level after 
injection of saline placebo and after subcutaneous injection of 
different doses of octreotide in five patients with acromegaly. 
Table 3. Plasma Insulin and Glucose Results 
Octreotide AUC Ins1 AUC Ins AUC Ins Peak Glue2 Mean GlucV Mean Gluc% Mean Gluc% 
Dose 0-3 hrs 0-8 hrs 0-12 hrs 0-3 hrs 0-8 brs 0-12 hrs 
placebo 431 + 111 1673 + 964 3524 + 1337 8.0 + 1.1 119.8 + 11.0 116.1 + 10.1 120.4 + 11.8 
25 pg 59 + 214 373 + 191 1274 + 259 10.1 + 1.7 144.4 + 7.4 (*) 124.1 + 5.2 120.8 + 5.8 
50 pg -55 + 67 l*)" -96 + 271 896 + 1273 11.3 + 1.4 (*) 153.6 + 16.6 143.8 + 17.2 133.4 + 15.1 
100 pg -44 + 202 (*) 493 + 946 2235 + 1864 9.9 + 1.7 155.4 + 20.4 152.3 + 22.8 139.0 + 17.5 
200 pg 13 + 121 406 + 829 2081 + 1582 10.3 + 1.8 160.1 + 19.5 (*) 157.8 + 18.9 <*&) 149.2 + 16.5 (*•) 
400 мд -114 + 33 (*) -398 + 193 <#) 355 + 429 10.4 + 1.6 (*) 162.1 + 12.3 (*) 169.0 + 14.5 <*#&) 161.0 + 15.7 <*#) 
1
 Area under the curve of plasma Insulin <mU/L.hrs) 
2
 Mean peak plasma glucose levels during 3 hrs after a standard breakfast 
3
 Mean plasma glucose in percentage of the baseline level 
« p<0.05 vs placebo (*), 25 цд (#), 50 цд (i), 100 ид <•), 200 ид cctrectide (») 
Effect of octreotide on plasma glucose levels (Table 3;Fig.l) 
After the standard breakfast plasma glucose rose to a mean peaJc level 
of 142 + 18 % of the basal value (8.0 +1.1 mmol/l) after saline, while 
significantly higher peak levels up to 190 + 18 % (11.3 + 1.4 mmol/l) 
were recorded after the 50 and 400 \ig octreotide doses (p<0.01 and 
p<0.05 respectively). No statistically significant differences between 
the individual doses were noted (p>0.10). 
The mean plasma glucose as a percentage of the basal level (mean 
glucose %) during the first 8 h showed higher values after octreotide 
compared with placebo, but statistical significance was only reached 
with the 200 and 400 ug injections (p<0.05). The mean glucose % was 
statistically significantly higher after the 200 and 400 цд octreotide 
doses than after the 25 цд injection (p<0.05). 
Adverse events 
Octreotide was in general tolerated well. Flatulence was noted by one 
patient (nr 4) after the 400 цд dose, while nausea and retching develo­
ped in another patient (nr 1) after 200 and 400 \ig. In this previously 
untreated patient side effects ceased when the octapeptide was adminis­
tered continuously by subcutaneous pump infusion. 
DISCUSSION 
In this single-dose response study we tried to determine the optimal 
dose of octreotide for the treatment of acromegaly. Others and oursel­
ves demonstrated that a simple acute test has a predictive value with 
regard to the extent to which plasma GH levels will be suppressed du­
ring chronic therapy with octreotide [4,7,16]. Like other dose-response 
studies, however, ours was also hindered by the great interindividual 
variety of sensitivity to the analogue. Probably this is due to a wide 
variation in the number of SRIF receptors between the pituitary tumours 
of different patients [19]. 
Despite the variation in sensitivity to the analogue, some sugges­
tions for the treatment of acromegalic patients can be deduced from the 
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current study. If the only aim is an optimal nadir GH, the lowest mean 
GH or the maximal duration of GH suppression after a single injection, 
the 400 цд octreotide dose will be the best choice. Furthermore the 50 
цд dose will be generally better than 25 цд, while the 100 and 200 цд 
doses do not offer any significant advantage over the 50 цд injection. 
Looking at results of dose finding studies it should be kept in mind 
that sustained reduction of plasma GH concentrations is not always ne­
cessary to achieve significant reductions in IGF-I concentrations. In 
some patients the degree of reduction of plasma concentrations of IGF-I 
is greater than the reduction in plasma concentrations of GH and in 
others full escape of plasma GH levels in between injections of octreo­
tide did not preclude significant reduction or even normalization of 
plasma concentrations of IGF-I [3, see for review 20]. 
Our findings in a single-dose response study are only partially re­
miniscent of data from a multiple dose study comparing 100, 200 and 500 
цд octrotide [10]. In that study in four out of eight patients a dose 
of 100 цд injected thrice daily provided maximal GH suppression, while 
in the other four patients a higher dose was slightly more effective. 
However, another dose-response study comparing 100, 500 and 1000 цд, 
thrice daily, revealed a significantly better reduction of the 24-hr GH 
concentrations after injections of 1000 цд than of 100 цд, while the 
500 цд dose did not yield significantly better results than either 100 
or 1000 цд [10]. Our results strongly suggest that one single injection 
of 400 цд octreotide is superior to the 100 цд or 200 цд dose in sup­
pressing mean 4-, 8- and 12-hr GH concentrations. A notable finding in 
our study is the lack of striking differences between the 50, 100 and 
200 цд octreotide doses in their GH suppressing capacity. This might be 
due to the single dose character of our study and the small number of 
patients. To make quite certain, we add that these results do not allow 
us to conclude that treatment with the somatostatin analogue in acrome­
galy should be started at the high dose of 400 цд. 
Several investigators have reported abnormal glucose tolerance in 
normal individuals as well as in patients while taking octreotide 
[3,8,21], which is at least partially due to suppression of acute in­
sulin release, as we showed again in this study. However, with short-
term octreotide therapy we found no overt diabetes or glucose intole­
rance as assessed by oral glucose loading [8]. In that study, however, 
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fasting glucose levels were lower during octreotide treatment. During 
long-term therapy, on the other hand, development of diabetes has been 
reported in a small number of acromegalic patients, which could easily 
be treated with sulfonylurea derivatives [1,3]. In the present study 
the overall effects on glucose tolerance for the complete group of pa­
tients are not easily interpreted, but clearly in all patients the 400 
цд dose caused the highest mean glucose value over the first 8 hrs af­
ter injection. Evidently fasting blood glucose levels were comparable 
on the different test days. The patient with type II diabetes in our 
study clearly had higher postprandial plasma glucose levels after oc­
treotide than after placebo. This was accompanied by an impressive re­
duction of the elevated plasma insulin concentrations to levels compa­
rable to those in the other, non-diabetic, patients (data not shown). 
Octreotide was in general tolerated well, although after the 400 мд 
dose minor adverse events were recorded. It is well established, how­
ever, that on long-term treatment acute side effects of high-dose in­
jection are not frequent [3,10,11], and rarely force patients to with­
draw from this effective therapy. 
In conclusion, in this single-dose response study in an admittedly 
small number of acromegalics we found that subcutaneous injection of 
400 цд octreotide yields the best results with regard to suppression of 
GH secretion, while the 50, 100 and 200 цд doses are superior to 25 цд, 
but do not differ from each other. Postprandial insulin secretion is 
virtually completely suppressed over the first three hours after any 
dose of the octapeptide. The highest mean plasma glucose levels over 
the first eight hours of the study are achieved after injection of 200 
and 400 цд octreotide. 
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CHAPTER 3 
EFFICACY OF LONG-TERM TREATMENT WITH OCTREOTIDE IN ACROMEGALY 

CHAPTER 3.1 
LONG-TERM TREATMENT OF ACROMEGALY WITH SANDOSTATIN (SMS 201-995). 
NORMALIZATION OF MOST ANOMALOUS GROWTH HORMONE RESPONSES 
G.F.F.M. Pieters, P.A. van Liessum, A.G.H. Smals, J.A. van Gennep1, 
Th.J. Benraad2, P.W.C. Kloppenborg 
Department of Medicine, Division of Endocrinology and Department of 
Experimental and Chemical Endocrinology2, University Hospital Nijmegen, 
Nijmegen. Sandoz в т, Medical Research Department, Uden. The 
Netherlands 
Acta Endocrinologica 1987;116(Suppl 2861:9-18 

ABSTRACT 
Twelve patients with active acromegaly were treated with the long-ac­
ting somatostatin analogue SMS 201-995 (SMS), at a dose of 50 \ig sc 
twice daily in the first 2 weeks of treatment and 100 цд sc thereafter. 
Four hours after the first injection of SMS, GH levels became normal in 
8 of the 12 patients. Basal glucose levels were significantly lower at 
the 28th day of treatment. This glucose lowering effect vas stronger in 
the diabetic than in the nondiabetic patients. The postprandial rise of 
insulin levels was reversed by SMS, leading to a more pronounced post­
prandial rise of glucose, whereas the postprandial secretion of gluca­
gon was also reversed by SMS. The rise of glucose levels during oral 
glucose loading was similar before and during SMS, despite a strong 
inhibitory effect of the drug on the insulin rise after glucose load­
ing. Basal TSH levels were not influenced by SMS, the TRH-induced TSH 
response, however, was significantly blunted. Although the basal pro­
lactin (PRL) levels were significantly reduced by SMS, the TRH-induced 
PRL rise was similar before and during administration of the analogue. 
Paradoxical GH responses to TRH disappeared in 7 out of 8 patients du­
ring SMS. Paradoxical GH responses to GnRH, however, persisted in 4 out 
of 4 patients. Paradoxical responses of GH after glucose loading disap­
peared in 2 out of 2 patients. The GH response after GHRH administra­
tion was strongly suppressed by SMS. During long-term treatment (up to 
2 years), the GH level obtained within 5 hours after the last injection 
of SMS remained normal in the patients whose GH levels normalized at 
the first day of treatment. There was a good response of the disease to 
this treatment, and no serious adverse reactions were observed. We con­
clude that SMS normalizes most anomalous growth hormone kinetics in 
acromegaly. The drug offers a new tool in the treatment of this disea­
se. 
INTRODUCTION 
Until recently, medical treatment of acromegaly patients was only pos­
sible with the dopaminergic drug bromocriptine (Liuzzi et al. 1974). 
Administration of 10-20 mg daily of this preparation leads to normali-
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zation of GH levels in about 40 per cent of the patients as shown by 
Nortier et al. (1984). 
The naturally occurring hypothalamic GH (somatotropin) release in­
hibiting hormone (SRIH) is also able to normalize GH levels in acrome­
galic patients, when it is administered iv ( Besser et al. 1974; Pie­
ters et al. 1982). The use of this tetradecapeptide for treatment of 
acromegaly is limited by its short half-life. Recently, the SRlH-analo-
gue minisomatostatin (SMS 201-995) was developed by Bauer et al. 
(1982). This analogue has a markedly longer duration of action and a 
strong inhibitory effect on the GH levels, and thus can be used for 
long-term treatment of acromegaly. Several studies (von Werder et al. 
1984; Plewe et al. 1984; Althoff et al. 1984; Ch'ng et al. 1985) deal­
ing with the short-term treatment of acromegaly patients with this oc-
tapeptide have demonstrated favourable results. Recently also a good 
long-term effect of SMS 201-995 (SMS) has been reported by Lamberts et 
al. (1985a,b). 
Besides chronic overproduction of GH in acromegaly, a number of ab­
normalities in the regulation of this hormone has been described. Para­
doxical increases in GH levels during oral glucose loading were repor­
ted by Beck et al. (1966). Irie ь Tsushima (1972) showed that anomalous 
GH responses after the administration of TRH are present in approxima­
tely 60 per cent of the patients. Such anomalous responses are also 
present after GnRH (Rubin et al. 1973) and CRH administration (Pieters 
et al. 1984). albeit in a lower percentage of the patients. 
Besides the short- and long-term effects of SMS on the GH secretion, 
we therefore studied the effect of this SRIH analogue on the above-men­
tioned anomalous GH responses and on the GH response to GHRH in 12 pa­
tients with acromegaly. 
PATIENTS AND METHODS 
Twelve patients with active acromegaly, 9 women (mean age + SEM: 5 0 + 5 
years) and 3 men (39 + 7 years), participated in this study. Informed 
consent was obtained from all patients after approval of the protocol 
by the hospital ethics committee. All patients were resistant to bromo­
criptine therapy or developed serious adverse reactions. Clinical data 
on these patients are given in Table 1. 
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Table 1. Some Clinical Data on 12 Patients with Acromegaly 
Patient Age Sex Previous treatment 
No. years 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
28 
23 
44 
65 
44 
49 
57 
62 
65 
26 
61 
48 
F 
F 
F 
F 
M 
M 
F 
F 
F 
M 
F 
F 
Pituitary surgery 
Pituitary irradiation 
Bromocriptine R 
Pituitary surgery 
Bromocriptine R 
Bromocriptine R 
Bromocriptine AR 
Pituitary surgery 
Bromocriptine R 
Bromocriptine AR 
Bromocriptine R 
Pituitary surgery 
Bromocriptine AR 
Pituitary surgery 
Bromocriptine R 
Pituitary surgery 
Pituitary irradiation 
Bromocriptine R 
Bromocriptine R 
Bromocriptine R 
R: resistant AR: adverse reactions 
TRH (TRH, 200 цд, Roche Ltd, Basel, Switzerland), GnRH (RelefactR, 
100 ug, Hoechst AG, Frankfurt, FRG), ovine CRH (CRT, 100 цд, Bachern 
Ltd, Torrance, CA) and GHRH (hpGRFx-^^, 100 цд, Bachern Ltd) were admi­
nistered on separate days at 09.00 h with the patients fasting and at 
bed rest. Blood samples for hormone assay were obtained via an indwell­
ing iv cannula at -30, 0, 5, 10, 20, 30, 60, 120 and 180 min after ad-
ministratin of the releasing hormone. An oral glucose tolerance test 
(100 g of glucose) was also performed at 09.00 h. The glucose tolerance 
test, the GHRH test and those releasing hormone tests to which a para­
doxical response occurred, according to the criteria reported earlier 
by us (Pieters et al. 1982), were repeated during SMS treatment after 4 
weeks. 
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SMS 201-995 was provided by Sandoz AG, Basel, Switzerland. SMS was 
administered sc at a dose of 50 цд twice a day. After two weeks of 
treatment, the dose was increased to 100 цд twice daily. Blood samples 
for hormone and glucose assay were obtained at 08.00, 09.00, 10.00, 
12.00, 13.00, 14.00, 16.00, 17.00 and 18.00 h the day before SMS treat­
ment, the first day of treatment, and after 4 weeks of treatment. The 
breakfast on these days was standardized. 
After termination of this study, SMS (100 цд twice daily) was con­
tinued in 9 patients with a maximal follow-up of 2 years. 
All hormone levels were determined by specific radioimmunoassays as 
described before: the coefficient of variation was 15% for GH (Pieters 
et al. 1982), 6% for PRL, 5.5% for TSH (Donders et al. 1985), and 11% 
for glucagon (Hendriks 1984). 
Radioimmunoassayable insulin was measured as follows: to duplicate 
25 μΐ plasma samples were added 375 μΐ of buffer (veronal 0.1 mol/1, pH 
8.6; 0.25% HSA, Albumin Merieux, Rhone-Poulenc, France), 50 μΐ of an­
tiserum (anti-insulin serum for radio-immunoassay, RD 10, Wellcome, 
Beckenham, UK), and 50 μΐ іг5І-іп5иііп tracer in assay buffer contain­
ing 1 mg of human gamma-globulin. Incubation was carried out for 72 h 
at 40c. For precipitation of antibody bound hormone l ml of polyethy­
lene glycol (12% PEG, 6000 Merck aqua dest) was added to 0.5 ml of in­
cubation mixture. After vortexing and centri fugation, the supernatant 
was aspirated and the precipitate counted. 
The standard was constructed using duplicate 25 μΐ aliquots of 8 
solutions containing from 10 to 200 mil of insulin/1 of assay buffer. 
The intra-assay coefficient of variation determined on 25 samples 
was 3.3% at values between 30 and 50 mtl/l. The inter-assay coefficient 
of variation at a level of 40 mU/1 determined on two samples was 8%. 
The lower limit of sensitivity was 5 pg/tube. 
Statistical analysis was performed using Wilcoxon's paired rank test 
(p-values denoted by P) and Wilcoxon's two sample test (P*). The mean 
results + SEM are given. 
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RESULTS 
Basal plasma GH, glucose, insulin and glucagon during SMS administra­
tion 
Plasma GH levels declined in all patients at the first day of treatment 
from a mean basal value of 62 + 24 \ig/l to a nadir value of 12.5 + 5.5 
ug/l after 4 h (P<0.01) and thereafter gradually increased to the pre­
treatment value after 12 h. GH levels normalized (<7.5 цд/1) in 8 of 
the 12 patients (Fig. 1). 
After 4 weeks of treatment, the basal GH level was lowered to 37 + 
13 цд/1 (P<0.05 vs control day) (Fig. 2). The administration of 100 цд 
of SMS at day 28 led to a further decline of GH levels to 10.5 + 5 цд/1 
after 4 h. Thereafter GH levels gradually increased to baseline values 
after 10 h. 
After 4 weeks of SMS treatment, the fasting glucose level obtained 
at 0.800 h was significantly lower than at the control day: 6.6 + 1.6 
vs 8.1 + 1.2 mmol/l, respectively (P<0.01) (Fig. 3). This glucose lowe­
ring effect of SMS tended to be more pronounced in those acromegalic 
patients who were diabetic compared with the non-diabetic patients (Δ 
glucose -2.4 + 0.6 vs -0.6 + 0.2 mmol/l, 0.05<P*<0.10). Throughout the 
day, glucose levels did not differ significantly except at 20.00 h when 
significantly lower values were achieved: 10.2 + 1.9 on control day vs 
8.1 + 1.3 mmol/l at day 28 (P<0.01). The postprandial increase in the 
glucose level was significantly lower before SMS than at day 28 (Δ glu­
cose between 08.00 and 10.00 h: 2.1 + 0.7 vs 2.7 + 0.7 mmol/l, respec­
tively (P<0.02). 
Basal insulin levels, obtained at 08.00 h, before and after 4 weeks 
of treatment, did not differ significantly: 42.5 + 12.4 vs 38 + 14.2 
mU/1 (Fig. 3). Before SMS, plasma insulin levels rose significantly and 
concomitantly with the glucose rise (P<0.02). During SMS, however, the 
postprandial rise of insulin levels was completely absent and even re­
versed (P<0.01). The inhibitory effect of SMS on insulin was of shorter 
duration than that on GH levels (3.6 + 0.4 vs 9.1 + 1.1 h, P=0.01). 
Basal glucagon levels, obtained at 08.00 h, before and after 4 weeks 
of treatment, did not differ significantly: 14.5 + 2.0 vs 16.7 + 2.1 
pmol/l (Fig. 3). Before SMS, plasma glucagon levels rose significantly 
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Fig.l Individual basal GH levels before and after the first injection 
of (50 цд) SMS in patients with acromegaly 
and simultaneously with the glucose rise. During SMS, however, the 
postprandial secretion of glucagon was reversed (P<0.05). 
Response of plasma GH, glucose and insulin to glucose loading and res­
ponses to releasing hormones before and during SMS therapy. 
Glucose loading (Fig. 4). 
After 4 weeks of SMS therapy, fasting glucose levels before oral glu­
cose administration were significantly lower than before SMS, both at-
30 min and at 0 min (Ρ < 0.01). Glucose loading, however, evoked a glu-
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hGH (¿ig/i) 
7 5 -
5 0 
25 
θ 9 10 12 13 14 Тб 18 2 0 clock time(hr) 
Fig. 2 GH levels during the day before treatment ( ·—· ) and at day 28 
of SMS treatment after the injection of 100 pg of SMS ( о — о ) 
cose response similar to that before treatment: Δ max before treatment: 
8,1 + 1.4 mmol/l and after 4 weeks of treatment 8.7 + 1.0 гщпоі/і (Ρ > 
0.10). 
Glucose tolerance was impaired (glucose at 120 min > 8 mmol/l) in 5 
out of the 8 patients before treatment and in all patients during SMS. 
Before SMS treatment, there was a strong initial rise of serum insu­
line levels after glucose loading from 2 3 + 8 mU/1 at 0 min to a max­
imal value of 117 + 27 mU/l at 60 min. Thereafter insulin levels gradu­
ally declined to baseline values at 240 min. During SMS treatment, the 
initial insulin rise after glucose loading was absent and the subse­
quent increase was blunted. After 240 min, serum insulin levels during 
SMS were still elevated, P<0.05 vs before SMS. 
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GlUCOSe (mmol/1) 
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time (min) 
Fig.4 Glucose and insulin levels in response to glucose loading before 
( · — · ) and during SMS treatment ( о — о ). ** P<0.02, for fur­
ther legends see Fig.3 GH levels showed a paradoxical increase 
during glucose loading in 2 patients. This paradoxical response 
disapppeared during SMS treatment (data not shown). 
•*— Fig.3 Glucose, insulin and glucagon levels during the day before SMS 
treatment ( · — · ) and at day 28 of treatment ( 0 — 0 ) · The as­
terisks indicate the statistical significance of the differen­
ces in glucose, insulin and glucagon levels at the respective 
time intervals. А P<0.10, * P<0.05, ** P<0.01 
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TRH-administration (Fig.5 and 6). 
Basal plasma TSH levels were not influenced by 4 weeks of SMS adminis-
tration. From 20 min and onwards the increment of TSH levels after TRH 
administration was significantly blunted during SMS administration: the 
Umax of TSH increase before treatment (7.8 + 2.8 mU/1) was significant-
ly higher than during SMS treatment (3.3 + 0.9 mU/1, P<0.05). 
Basal PRL levels were significantly lowered by SMS administration 
(P<0.05). In the patients with hyperprolactinaemia (basal PRL > 550 
mU/1), the PRL lowering effect of SMS was stronger than in those with a 
normal PRL (APRL - 434 + 163 vs -40 + 12 mU/1, P*<0.05). PRL responsi-
veness to TRH was not influenced by SMS administration, the Umax being 
virtually identical: 531 + 84 mU/1 before treatment vs 514 + 97 mU/1 
during SMS (P>0.10, Fig. 5). 
Eight patients showed paradoxical responsiveness of GH levels to TRH 
administration before SMS treatment. During SMS, it completely disap-
peared except in patient No. 6. In this patient the paradoxical respon-
siveness persisted, although the maximal increase was only 30% of the 
response before treatment (Fig. 6, middle panel). 
GnRH administration (Fig. 6, lower panel) 
Before treatment, 4 patients responded paradoxically to GnRH. In all 
these patients, the paradoxical responsiveness persisted during SMS. 
GHRH administration (Fig.6, upper panel) 
All patients, except no.6 and 8 who had the lowest basal GH levels, 
showed clear GH responses after GHRH administration. After SMS for 4 
weeks, GH responsiveness to GHRH completely disappeared in 3 of the 8 
responders and was almost completely blunted in 4. Only in one patient 
(no.5) did a clear responsiveness to GHRH persist, although the maximal 
GH response was 35% lower than before treatment. 
CRF administration 
Only one patient responded paradoxically to CRF administration. During 
SMS, this response disappeared completely (data not shown in the figu-
re). 
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Fig.5 TSH and PRL levels in response to TRH administration before 
( ·—·) and during SMS treatment ( О—о ). For further legends see 
Fig.3 
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majority of the patients, but that responses to GnRH remain pre­
sent 
Long-term treatment with SMS 
In 3 of the 9 patients treated for a period longer than 3 months (3-22 
months, median 18 months), SMS treatment did not normalize GH levels. 
It is remarkable that none of these 3 patients showed normalization 
after the first injection of SMS. The remaining 6 patients, who showed 
normalization of GH levels after the first injection of SMS, remained 
at a normal GH level during long-term treatment (up to 2 years)(Fig.7). 
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Fig.7 GH levels achieved within 5 h after the last injection of 100 
\iq of SMS during long-term treatment 
Clinical response and adverse reactions 
In table 2 major signs and symptoms of acromegaly and the response to 
the treatment are mentioned. All patients except No. 10 observed an 
amelioration of their disease. No serious adverse reactions or changes 
in blood chemistry were observed. 
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Table 2. Clinical Response te SNS Treatment in the Patients with Acrcmegaly 
Patient GH 
Ne. during 
SNS 
Clinical response 
Facial Acrai Hyper-
features enlarge- hydrcsis 
ment 
Head-
ache 
Loss 
cf 
vitality 
Acne 
Carpal 
tunnel 
Hyper-
trichosis 
Adverse 
reactions 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Normal 
Normal 
Normal 
Normal 
Normal 
Normal 
Elevated 
Normal 
Elevated 
Elevated 
Elevated 
Normal 
+ 
+ 
4 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ ++ 
+ + + 
+ + 
Discontinued after 
+ 
+ 
++ 
+ 
+ + 
+4 
4 
4 
44 
4 weeks 
4 
-
4 
None 
None 
Transient nausea 
after injection 
Weight gain 10 kg 
None 
None 
None 
None 
Nene 
Nene 
None 
None 
4 : Symptom ameliorated 44 : Symptom disappeared - : Symptom present and unchanged 
DISCUSSION 
The results in this study on the short-term effects of SMS 201-995 on 
GH secretion in acromegaly are in agreement with those of other inves­
tigators who reported normalization of GH levels in the majority of the 
patients after injection of 50 цд of SMS. Increasing the dose of SMS to 
100 цд led to a longer lasting effect, but not to a stronger effect. 
The lowering effect on serum insulin levels after SMS was of shorter 
duration thanthat on GH levels, whereas this insulin inhibitory effect 
led to an increased postprandial rise of glucose levels after several 
days of SMS treatment. These three findings have been reported earlier 
by Lamberts et al. (1985a). In our study, this effect was still present 
after 4 weeks of SMS treatment. Furthermore, we demonstrated an in­
hibitory effect of SMS on glucagon release. Basal glucose levels after 
4 weeks of treatment were significantly lower than before therapy. In 
view of the inhibitory effect of SMS on insulin release we assume that 
the GH lowering effect and the inhibitory effect on the glucagon re­
lease of SMS account for this decrease in basal glucose levels. Glucose 
tolerance assessed by the oral glucose tolerance test remained unchan­
ged during SMS, despite a strong inhibitory effect of this drug on in­
sulin release. Since one would expect glucose to rise higher during the 
period of suppressed insulin release, we wonder whether a slower ab­
sorption of glucose from the gut accounts for the lack of such a dif­
ference . 
The GH levels of 2 patients responded paradoxically to glucose load­
ing. In both patients, this paradoxical response disappeared during SMS 
administration. Disappearance of the paradoxical responsiveness of GH 
during glucose loading has also been described during infusion of 1000 
цд of SRIH by Gomez-Pan et al. (1975). 
Basal TSH levels were unchanged by SMS, but the response of TSH to 
TRH administration was significantly blunted. Brazeau et al. (1978) 
described this earlier using the native somatostatin 5К1Нл._1Л. Despite 
the inhibitory effect of SMS on TRH-induced TSH release we did not find 
any alterations in the basal levels of Тз and T 4 during SMS treatment 
(data not shown). Basal PRL levels were significantly lower during SMS 
treatment. This effect was stronger in the hyperprolactinaemic than in 
the normoprolactinaemic patients. It is remarkable that the PRL res-
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ponse to TPH was unaffected by SMS. This dichotomy points to differen­
tial effects of SMS on the TSH-producing and the PRL-producing cell. 
Exaggerated GH responses to GHRH administration have been reported 
in acromegalic patients with high GH levels (Pieters et al. 1985). We 
observed that after treatment with SMS, GHRH responsiveness, if pre­
sent, disappeared in the majority of the patients. This finding is at 
variance with our earlier reported data on GH responsiveness to GHRH 
during continuous iv administration of 300 \ig per hour of native SRIH, 
but differences in the dose schedules may account for this divergence. 
The TRH-induced paradoxical GH release was completely blunted in all 
patients except one. These data are at variance with those of Giustina 
et al. (1974) and Faglia et al. (1975) who failed to demonstrate any 
effect of administration of 100 цд of SRIH per hour iv on TRH-induced 
GH release in acromegalic patients. Later Gomez-Pan et al. (1975), how­
ever, demonstrated blunting of the paradoxical GH response to TRH du­
ring infusion of 1000 цд of SRIH per hour. So differences in the dose 
of somatostatin may account for these seemingly contradictory results, 
as 100 цд of SMS sc in its inhibitory effect equals an iv dose of more 
than 500 цд of SRIH per hour. Interestingly, SMS could not prevent the 
paradoxical responsiveness of GH after GnRH administration. 
It has been suggested that the anomalous GH responses after TRH 
and/or GnRH administration occur by dedifferentiation of the GHRH-re-
ceptor of the adenomatous GH-producing cell. By this dedifferentiation 
TRH and/or GnRH will stimulate GH release via the same mechanism as 
GHRH. If this hypothesis was true one would expect that the GH respon­
ses to TRH and GnRH would disappear during SMS administration in a 
smilar manner to the blunting of the GH responses after GHRH admini­
stration, The persistence of paradoxical responses to GnRH during SMS 
treatment strongly suggest that GnRH evokes anomalous GH responsiveness 
via a mechanism that differs from that by which GHRH and TRH exert such 
action. This theory is strengthened by the finding by Ishibashi et al. 
(1977, 1978) who demonstrated that during chronic treatment with bromo­
criptine the paradoxical responsiveness to GnRH disappears but that to 
TRH persists. Thus, the effects of SMS and bromocriptine on the dyna­
mics of GH secretion are to a certain extent complementary. 
The results on long-term treatment with SMS and bromocriptine show a 
good concordance with those after the first injection of SMS. Almost 
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all acromegalic patients whose GH levels normalized during SMS showed a 
good clinical response to this treatment, and those who had only a mo­
derate amelioration of their disease were those who had lesser com­
plaints before the start of the treatment. 
Together, our data show that the somatostatin analogue SMS 201-995 
normalizes GH levels in most patients with acromegaly and that it re­
verses most anomalous characteristics of GH secretion in acromegaly. 
SMS 201-995 offers a new tool for the treatment of acromegaly, espe­
cially in patients who are resistant to the conventional therapeutic 
modalities. 
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CHAPTER 3.2 
DOES SMS 201-995 NORMALIZE GROWTH HORMONE SECRETION IN ACROMEGALY? 
GH DAY PROFILES AND GH CONCENTRATIONS AFTER ORAL GLUCOSE LOADING 
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ABSTRACT 
GH secretion in acromegaly was studied in 8 patients before and during 
treatment with SMS 201-995, a somatostatin analogue, 100 \ig twice dai­
ly, by evaluating GH day profiles and GH suppressibility after oral 
glucose tolerance tests (OGIT). Normalization of GH secretion, estima­
ted by OGTT, was only observed in the three patients who had a decrease 
in plasma GH to less than 2 цд/1 after SMS 201-995 injection, and who 
had the lowest mean plasma GH levels during the day and the largest 
percent decline of mean plasma GH levels. We conclude that real norma­
lization of GH secretion during SMS 201-995 therapy only occurs in a 
subset of patients. The data illustrate that the applicability of the 
generally held cut-off value of 5 мд/І, between normal and abnormal 
plasma GH, has to be reconsidered in the case of chronic intermittent 
subcutaneous therapy with SMS 201-995. 
INTRODUCTION 
Since 1982 the long-acting somatostatin analogue SMS 201-995 (SMS) has 
been widely used in the medical treatment of acromegaly [1-3]. Good 
results with regard to plasma growth hormone (GH) suppression and cli­
nical efficacy during long-term treatment have been reported by a num­
ber of investigators [4-6]. In most of these studies the results of 
treatment were evaluated by measuring plasma GH levels at fixed inter­
vals during the day. Unfortunately, normalization of GH secretion du­
ring SMS therapy cannot be deduced directly from these data. 
Testing the suppressibility of GH levels after oral glucose loading 
is still a widely used procedure in the diagnostic work up of acrome­
galy. It has also proved to be a reliable tool in the assessment of GH 
secretion after pituitary surgery [7] and in estimating the effect of 
chronic bromocriptine therapy [8]. Similar data with respect to SMS 
therapy are still lacking. 
We therefore decided to study the plasma GH suppressive effect of 
SMS in acromegalic patients by measuring the plasma GH profiles during 
the day as well as the GH levels after oral glucose tolerance tests 
(OGTT) before and during treatment. 
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MATERIALS AND METHODS 
Eight patients with active acromegaly, 5 women (mean age 43 yr, range 
23-65) and 3 men (mean age 40 yr, range 26-44), participated in this 
study. Informed consent was obtained from all patients after approval 
of the protocol by the hospital ethics committee. All patients were 
resistant to bromocriptine therapy or had developed serious adverse 
reactions and were consecutively enrolled in the trial. Bromocriptine 
therapy was withheld for at least three weeks before the new treatment 
was started. Clinical data on the patients are given in Table 1. 
Table 1. Patient Data 
Patient 
no. 
1 
2 
3 
4 
5 
6 
7 
θ 
Age 
(yrs) 
44 
44 
23 
26 
28 
57 
49 
65 
Sex 
F 
M 
F 
M 
F 
F 
M 
F 
Pituitary 
hormone 
deficiency 
ACTH 
ACTH 
Previous Therapy1 
Br R 
TSS 1971, Br R 
TSS 1971/1981, Br R 
TFS 1984, Irr, Br R 
TFS 1983, Irr, Br R 
Br R 
Br AR 
Br AR 
TSS: Transsphenoidal surgery. TFS: Transfrontal surgery. Irr: 
External irradiation. Br R: Bromocriptine resistant. Br AR: 
Adverse reactions on bromocriptine. 
SMS 201-995 was provided by Sandoz A.G. Basle, Switzerland and was 
administered sc at a dose of 50 цд twice a day at 08.00 and 20.00 h. 
After two weeks of treatment, the dose was increased to 100 \ig twice 
daily. 
Serial blood samples were collected via an indwelling catheter situ­
ated in an antecubital vein. Blood samples for GH assay were obtained 
at 08.00, 09.00, 10.00, 12.00, 13.00, 14.00, 16.00, 18.00 and 20.00 h 
on the day before SMS treatment, on the first day of treatment and af­
ter 4 weeks of therapy. The mean of these 9 values represents "the mean 
GH level during the day". "Basal" was defined as the situation at the 
72 
moment immediately before administration of SMS (8.00 h). The breakfast 
consumed on these days was standardized (07.30 h). 
An oral glucose loading test (100 g of glucose) was performed before 
treatment and once during the fifth week of therapy at 09.00 h. Glucose 
loading was preceded by an injection of 100 \ig SMS at 8.00 h. The test 
was considered normal if the GH level was suppressed to below 0.5 цд/1. 
GH levels were determined using a specific radioimmunoassay [9]. All 
samples from the same patient were run in a single batch. 
Results are expressed as means + standard error of the mean. Statis­
tical significance was tested using wilcoxon's signed rank test (p va­
lue denoted by p) and Spearman's rank correlation test (p*). 
RESULTS 
On the first day of treatment with 50 цд of SMS, plasma GH levels de­
clined in all patients from a mean basal value of 71 + 33 цд/1 to a 
nadir value of 11 + 6 цд/1. GH levels were found to be suppressed to 
below 5 цд/1 in five patients. 
On day 29 of treatment the mean basal plasma GH was 48+19 цд/1 (NS 
vs day 1). After an injection of 100 \ig SMS sc the nadir value was 9 + 
4 цд/1. Three patients (nos. 1, 3 and 8) showed a decrease of plasma GH 
to less than 2 цд/1 (Table 2, Fig.l). Mean plasma GH levels during the 
day declined from 59 + 25 цд/1 before treatment to 37 + 15 μg/l 
(p<0.01) on day 1 and to 27 + 11 цд/1 (p<0.01) on day 29 of treatment. 
Oral glucose loading before treatment with SMS evoked a pathologi­
cal GH response in all patients. After 4 weeks of treatment the same 
procedure revealed complete normalization of the GH response (Table 3, 
Fig.2) in three patients. They also demonstrated lowering of plasma GH 
to less than 2 цд/1 on day 29 of therapy without glucose loading and 
had the lowest mean plasma GH level during the day, as well as the lar­
gest percent decline of mean plasma GH level. Normalization of GH res­
ponse after OGTT was neither related to basal GH on day 1 (rho=0.52, 
NS), nor to the area under the curve of plasma GH throughout 12 hrs of 
day 29 (rho=0.02, NS). However, the basal GH level on day 29 was 
closely related to GH suppressibility after glucose loading (rho=0.86, 
p*<0.01). 
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In all patients except number 4 an amelioration of signs and symp­
toms of acromegaly was noticed. No serious adverse reactions or changes 
in blood chemistry were observed. 
Table 2. Effect of SMS 201-995 Treatment on Plasma GH Day-profiles 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
MEAN 
(+SEM) 
Before SMS 
201-
GH 
27 
16 
40 
62 
209 
77 
12 
25 
59 
25 
-995 
Basal 
GH 
23 
27 
81 
65 
277 
100 
15 
30 
71 
33 
Nadii 
GH 
3 
3 
3 
39 
6 
32 
4 
0.5 
11 
6 
Plasma 
Day l 
GH1 
9 
15 
26 
50 
122 
61 
7 
5 
37 
15 
GH (цд/1) 
During SMS 
GH(%)2 
- 34 
- 5 
- 18 « 
- 10 
- 21 
- 11 
- 20 
- 41 
- 20 
5 
201-995 
Basal 
GH 
10 
36 
18 
50 
141 
110 
13 
5 
48 
19 
Day 
Nadir 
GH 
2 
5 
0.5 
21 
5 
30 
4 
0.5 
9 
4 
29 
GH 
5 
13 
6 
43 
61 
73 
10 
4 
27 
11 
GH(%) 
- 42 
- 11 
- 43 
- 16 
- 36 
- 3 
- 9 
- 43 
- 25 
7 
GH : Mean plasma GH levels during the day. 
GH(%): Percentual change of mean plasma GH levels. 
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Table 3. Effect of SMS 201-995 Treatment on Plasma GH Levels during OGTT's1 
Patient 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
-30 
24 
55 
59 
50 
91 
95 
8 
20 
Before 
0 
25 
43 
64 
60 
99 
85 
7 
21 
30 
34 
68 
58 
75 
233 
100 
6 
15 
treatment 
60 
22 
53 
42 
65 
125 
80 
5 
31 
90 
15 
53 
25 
65 
144 
70 
6 
24 
Plasma GH 
120(min) 
12 
33 
23 
65 
125 
65 
6 
20 
(цд/і 
-30 
12 
24 
21 
85 
93 
105 
8 
4 
0 
12 
13 
10 
55 
103 
70 
4 
1 
Duri 
30 
5 
5 
3 
48 
122 
55 
2 
<0. 
nq 
5 
SMS 
60 
2 
3 
1 
20 
58 
70 
3 
<0. 
201-995 
90 
0.5 
6 
<0.5 
20 
18 
70 
3 
5 <0.5 
120 
<0.5 
5 
<0.5 
18 
7 
55 
3 
<0.5 
1
 OGTT: Oral glucose tolerance test (100 g) 
Plasma growth hormone (цд/І) 
250 
5-
s : : ^ · ^ ^ : 
before Irealment 
250 
Fig.l Individual growth hormone day profiles before and during treatment with 
SMS 201-995, 100 цд twice daily, in eight patients with acromegaly. 
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Plasma growth hormone (μ9/Ι) 
250 -
50 -
25 -
5 -
2 -
before treatment 
glucose 
( 5 )
 ι J» · - · 
! " V · 
Î · . - · 
I 
I 
1 
1 
1 
1 
1 
1 
1 
1 
' 1 1 1 1 
-30 0 60 120 -30 0 60 120 
time (mm) 
Fig.2 Individual growth hormone responses on oral glucose loading (100 
g) before and during treatment with SMS 201-995, 100 цд twice 
daily, in eight patients with acromegaly. The oral glucose loa­
ding during treatment was preceded by an injection of 100 цд SMS 
201-995 at 8.00 h. 
DISCUSSION 
"Normalization" of the GH level has been reported in the majority of 
patients with active acromegaly after the injection of 100 pg SMS 
[3,4,6,10]. There is, however, no consensus on how to measure the nor­
malization of GH secretion. The optimal method might be to determine 
the integrated GH secretion throughout the day. As an approximation one 
could measure GH levels several times at fixed intervals, calculate the 
mean and determine the nadir GH value. These methods can only be used 
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with the proviso that plasma GH levels are indeed the best expression 
of disease activity. The measurement of IGF-I may be superior [11,12], 
although sometimes specificity is lacking [13,14]. 
In our study we chose the OGTT to reassess GH secretion during SMS 
therapy. It is as effective as using the mean plasma GH level during 
the day for estimating disease control during chronic bromocriptine 
therapy [14]. It was thought useful to perform the test starting one 
hour after the administration of the medicament, by analogy with an 
earlier study mentioned above on the evaluation of chronic bromocrip­
tine therapy. Our data show perfect correspondence between the nadir GH 
level of less than 2 цд/1 during SMS therapy and complete normalization 
of the OGrr. We therefore consider that, during chronic SMS treatment, 
only a decline of plasma GH below this value indicates normalization of 
GH secretion. Normalization of OGIT occurred in patients with the lo­
west mean plasma GH during the day and the sharpest percentual decline 
in mean GH levels (Table 2). A close relation was also found between 
the basal GH day level on day 29 and GH suppressibility after glucose 
loading. No correlation could be found between basal plasma GH on day 1 
of treatment or the integrated plasma GH levels during the day and nor­
malization of the GH response after glucose loading. 
Because the finding of normal IGF-I values is currently believed to 
be an excellent criterion for normalized GH secretion [11,13,15], we 
also measured IGF-I [16] in plasma samples, whenever available, of our 
patients during treatment. Two of the three patients who showed a nor­
mal GH suppression after OGTT had a high normal or slightly elevated 
IGF-I level (patient no.l: 52.8 nmol/1 and patient no.3: 77.3 nmol/1; 
normal: male <47.5 nmol/1, female <55.0 nmol/1). No plasma from the 
third patient was available. On the other hand plasma IGF-I values in 
the "non-normalizing" patients were high (patient no.4: 214.0 nmol/1, 
patient no.6: 149.8 nmol/1 and patient no.5: 94.0 nmol/1). This once 
more supports our assumption that the OGTT is a predictor of normaliza­
tion of GH secretion during treatment with SMS. 
This paper relates the normalization of GH secretion during inter­
mittent sc SMS therapy measured by OGTT, to daytime plasma GH levels. 
The low number of patients with normalizing GH secretion during treat­
ment with the somatostatin analogue was firstly disappointing. However, 
if we apply our criterion of normalization of GH secretion after oral 
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glucose loading to the data of Schuster [7] and Nortier [14], who stu­
died the long-term therapeutic effectiveness of transsphenoidal pitui­
tary surgery in 11 patients and the GH suppressive effect of bromocrip­
tine in 12 patients with acromegaly, respectively, the result of SMS 
treatment, even with the low dose of two times 100 цд a day, seems su­
perior. Neither in the operated patients nor in the patients treated 
with bromocriptine was glucose able to suppress the GH levels to below 
0.5 цд/1. Although none of both treatments modifies glucose metabolism 
as SMS does, still GH suppressibility by glucose seems to be an equiva­
lent reliable tool in therapy with the somatostatin analogue. 
In conclusion, this study indicates that GH hypersecretion is re­
versed by administering SMS 100 цд twice daily in some patients with 
acromegaly, both with regard to the basal GH level and the GH response 
to OGTT. Furthermore, this study suggests that the nadir GH value du­
ring SMS treatment has some value as a predictor of real normalization 
of GH secretion established by means of an oral glucose tolerance test: 
only patients who achieved nadir GH levels of less than 2 цд/1 showed 
normal GH suppression after glucose loading. The data suggest that the 
applicability of the generally held cut-off value of 5 цд/1, between 
normal and abnormal plasma GH, has to be seriously reconsidered in the 
case of chronic intermittent sc therapy with SMS 201-995. Obviously 
these conclusions should be revised if continuous sc therapy with SMS 
is involved. 
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ABSTRACT 
Serum samples of thirteen patients with active acromegaly on long-term 
sc treatment with SMS 201-995 (SMS, 1-36 months, mean daily dose 285 
\ig) were taken 12 hours after the injection of their regular evening 
doses. SMS 201-995 assay was performed using 125I-Tyr-SMS and a 
polyclonal rabbit anti-serum. For assessment of antibody formation both 
serum coated charcoal adsorption (adsorption of free SMS) and polyethy-
lene glycol precipitation (precipitation of IgG complexes) were used. 
The mean binding percentage in the patients proved to be similar to 
that of five healthy volunteers (p>0.10). No specific binding was de-
tected, whatever method used. No correlation was found between the bin-
ding percentages and SMS serum levels, duration of SMS treatment or 
daily SMS dose (p>0.10). These results strongly suggest that clinically 
relevant endogenous antibody formation is not a frequent event during 
long-term sc treatment of acromegalic patients with SMS 201-995. 
INTRODUCTION 
The long-acting somatostatin analog SMS 201-995 (SMS) is a potent in-
hibitor of growth hormone (GH) secretion. In the treatment of acrome-
galy it normalizes GH levels in many patients without rebound hyperse-
cretion and deletes most anomalous GH responses (1-8). Pituitary tumor 
reduction has been reported, even leading to recovery from ophthalmo-
plegia (3,9). 
Some patients are treated now for more than five years with inter-
mittent subcutaneous SMS injection without important local or systemic 
side effects. The octapeptide is at potential risk of inducing antibody 
formation, being structurally different from native somatostatin. Anti-
body formation could impair the effect of SMS treatment, cross-react 
with the native somatostatin and interfere with the measurement of 
plasma SMS. So far no study on this subject in acromegaly has been pub-
lished. In seven patients with peptide-secreting pancreatic tumours 
treated with the analogue, however, no evidence of humoral immune res-
ponses against SMS could be demonstrated (11). In the latter study dex-
tran coated charcoal was used to detect the presence of anti-SMS anti-
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bodies. This technique could have erroneously underestimated SMS-bin­
ding due to dissociation of less avidly bound SMS. Therefore, in addi­
tion to this procedure we used polyethylene glycol (PEG) precipitation 
to demonstrate possible SMS-binding in patients with active acromegaly 
to ascertain whether formation of endogenous antibodies to the peptide 
occurred during chronic subcutaneous treatment with SMS. 
SUBJECTS AND METHODS 
We investigated 13 patients with active acromegaly (2 men, 11 women, 
age 26-68 years) on chronic treatment with SMS. All but one had been 
treated with subcutaneous injections for 1-36 months, 2 to 3 times dai­
ly. The mean daily dose was 285 цд, ranging from 200-600 цд. One pat­
ient (no 13) was treated with continuous subcutaneous SMS administra­
tion by pump infusion (300 цд per day). Serum of five healty volunteers 
was also investigated. Data on all subjects are represented in table 1. 
Twelve hours after the injection of their regular evening doses (100 
цд) or discontinuation of pump infusion of SMS, serum samples were ta­
ken. Serum was separated by immediate centrifugation for 5 min at 
2000xg and was subsequently stored at -20oC. Informed consent was ob­
tained from all patients. 
SMS 201-995 assay 
The assay was performed using the SMS-RIA-kit as provided by Sandoz 
(Sandoz Ltd, Basle, Switzerland). A standard curve from 0-1250 pg/ml 
SMS was set up in duplicate. To 100 μΐ of standard or serum sample 100 
μΐ of "-^I-Tyr-SMS, 100 μΐ of a polyclonal rabbit anti-serum (titre 
1:700,000) and 500 μΐ of 0.01 M phosphate buffered saline (PBS) of pH 
7.2 were added. 
Following overnight incubation at 40C, antiserum bound and free li-
gand were separated by the addition of 500 μΐ of a charcoal suspension 
(1% w/v and 1% v/v of pool serum). The tubes were vortexed, incubated 
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for 10 min at 40C and then centrifugated for 10 min at 40C and 2000xg. 
The supernatants were decanted and counted for radioactivity. 
The assay sensitivity, defined as the smallest amount of SMS distin­
guishable from zero at a 95% confidence limit, was 24.6 pg/ml. Intra-
assay coefficient of variation, calculated from duplicate estimates, 
was 9.8%. 
Assessment of antibody formation 
Serum coated charcoal adsorption (SCC, adsorption of free SMS) 
To 100 μΐ of patient serum 600 μΐ of PBS and 100 μΐ of 12ЬІ-Туг-5М5 
were added. Following overnight incubation at 40C, 500 μΐ of charcoal 
(Norit A, Fischer, New York, U.S.A.; 1% w/v and 1% v/v pool serum) were 
added. The tubes were vortexed and after 10 min of incubation at 40C 
centrifugea (40c) at 2000xg for 10 min. The supernatants were decanted 
and counted for radioactivity. For positive control 100 μΐ of rabbit 
antiserum (in the RIA d 
ilution) instead of 100 μΐ PBS were added to 100 μΐ of a normal serum 
pool, resulting in a binding of 55.3%. Intra-assay coefficient of vari­
ation, calculated from duplicate estimates, was 6.7%. 
Polyethylene glycol precipitation (Precipitation of IgG complexes) 
To 100 μΐ of patient serum 300 μΐ of PBS and 100 μΐ of i:?4I-Tyr-SMS 
were added. Following incubation for 2 hrs at 370C 1.0 ml of PEG 6000 
(Merck 807491, Merck, Darmstadt, Germany) 22% w/v in PBS was added. The 
mixture was vortexed and centrifugea for 15 min at 2000xg. After cen-
trifugation the supernatants were aspirated and the pellets counted for 
radioactivity. As a positive control 100 μΐ of rabbit antiserum (in the 
RIA dilution) instead of 100 μΐ PBS were added to 100 μΐ of a normal 
serum pool. 58.2 % of the radioactivity was precipitated. Intra-assay 
coefficient of variation, calculated from duplicate estimates, was 
4.3%. 
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All assays were performed in duplicate. Results were expressed as the 
mean + standard error of the mean (SEM). Binding was considered to be 
specific if it exceeded the mean binding percentage of the healthy vol­
unteers plus three standard deviations. Statistical analysis was per­
formed by Student's t-test for paired or unpaired data (p). Correlation 
coefficients were calculated according to Pearson. All tests were two-
tailed. 
RESULTS 
The results are represented in table 1. Using SCC the mean binding per­
centage in the patients was 3.18 + 0.16%, similar to the value found in 
the healthy volunteers (3.33 + 0.12%, p>0.10). Precipitation with PEG 
resulted in a statistically significantly higher binding percentage 
than after SCC adsorption (5.18 + 0.15%, p<0.00001). Again the binding 
was comparable with that of healthy volunteers (4.71 + 0.30%, p>0.10). 
In serum of one patient (no 1) using SCC, binding percentage was 
slightly above 5% (5.03%). However in the PEG method, binding was well 
within the normal range. No correlation could be found between the bin­
ding percentages in the patients, determined by either method (r=0.09, 
P>0.10). Moreover, there was no significant correlation between the 
binding percentages - whatever method used - and SMS serum levels, du­
ration of SMS treatment or daily SMS dose (p>0.10). 
DISCUSSION 
Although the SMS octapeptide is rather small, endogenous antibody for­
mation could theoretically occur during long-term treatment, due to its 
structural difference from native somatostatin. In the only study pu­
blished so far on this subject, a small number of patients with endo­
crine pancreatic tumours was investigated (11). We investigated a lar­
ger number of 13 patients with acromegaly who were treated for a longer 
period of time (22 + 3.6 mths vs 16.7 + 2.6 mths) and received a higher 
daily dose of SMS (285 + 30 vs 171 + 36 цд). 
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Table 1. Data on Patients and Healthy Volunteers and Results cf SMS 201-995 Assay and Assessment cf 
Antibody Formati en 00 
Patient 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Mean (SEM) 
Healthy 
Volunteers 
1 
2 
3 
4 
5 
Mean (SEM) 
Age 
(years) 
31 
26 
46 
68 
59 
67 
28 
36 
31 
40 
61 
29 
46 
44 
21 
25 
20 
20 
22 
22 
(4) 
(1) 
Sex 
F 
F 
F 
F 
F 
F 
M 
M 
F 
F 
F 
F 
F 
M 
M 
M 
F 
F 
Daily Dose 
SMS 201-
(цд) 
300 
300 
200 
300 
200 
600 
300 
200 
200 
200 
300 
300 
300 
285 
-
-
-
-
-
-
995 
(30) 
Duration cf 
Treatment 
(months) 
36 
36 
33 
34 
30 
30 
27 
13 
17 
16 
7 
6 
1 
22 (4) 
-
-
-
-
-
-
SMS serum 
level 
(pmcl/L) 
66.7 
109.1 
92.4 
475.9 
152.9 
227.2 
115.6 
40.0 
260.5 
39.8 
458.8 
65.9 
116.2 
170.9 (40.8) 
<24.6 
<24.6 
<24.6 
<24.6 
<24.6 
<24.6 
Binding Binding 
PEG1 SCC2 
(%) <%) 
5.28 5.03 
4.61 2.89 
4.48 2.92 
5.21 3.52 
5.88 2.93 
5.93 3.14 
4.83 3.00 
4.89 3.10 
5.93 2.79 
5.18 2.87 
5.65 3.14 
5.00 3.07 
4.47 2.91 
5.18 (0.15) 3.18 (0.16) 
4.11 3.19 
5.31 3.53 
5.54 3.68 
4.49 3.15 
4.08 3.09 
4.71 (C.30) 3.33 (0.12) 
1
 Pclyethylene glycol precipitation 
2
 Serum charccal adsorption 
The charcoal adsorption method employed by Fuessl et al. to detect tra-
cer binding in serum is based on the removal of free tracer by the ad-
sorbent with subsequent measurement of the remaining radioactivity. In 
general there is the risk of underestimation of binding when a signifi-
cant proportion of tracer dissociates from the binding protein during 
incubation or when some adsorption of whole tracer-protein complexes 
takes place. The alternative used in this study, i.e. precipitation of 
an IgG-containing fraction of serum proteins by 15 % polyethylene gly-
col with radioactivity measurement in the precipitate, may underesti-
mate binding by incomplete precipitation of IgG, but is unlikely to 
cause dissociation of tracer-antibody complexes. With both methods, 
apparent ("non-specific") binding is found in the serum of untreated 
control subjects which in the charcoal adsorption method must be due to 
incomplete adsorption of free tracer and in the case of PEG to inclu-
sion of free tracer in the precipitate. Deliberate addition of rabbit 
antiserum to SMS was readily detected with both techniques. Moreover, 
the percent tracer specifically bound in SCC (53.8%) differed only a 
few percent from that in PEG (56.1%). Gross underestimations of anti-
body binding by any of the techniques therefore seems improbable. In 
one case a slightly higher binding than average was detected using 
charcoal adsorption of non-bound SMS. In the same serum however, no 
binding was found with the PEG precipitation method. The observed bin-
ding in the SCC method thus should not be considered as specific. The-
refore, similar to the study mentioned above (11), also during long-
term treatment in acromegaly no evidence of endogenous antibody forma-
tion was found. This is compatible with the fact that there has been no 
need to gradually increase the SMS dose in our patients to maintain the 
same therapeutic effect as long as for five years. 
These results strongly suggest that clinically relevant endogenous 
antibody formation does not occur during long-term sc treatment with 
SMS 201-995 in acromegaly. 
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CHAPTER 4 
SIZE REDUCTION OF GROWTH HORMONE PRODUCING PITUITARY TUMORS DURING 
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ABSTRACT 
We report on an acromegalic patient whose ophthalmoplegia completely 
resolved during treatment with SMS 201-995 (SMS), a long-acting somato-
statin analogue. A 60-year-old woman with acromegaly gradually develo-
ped signs of progressive disease, followed by complaints of paresthae-
sias on the right side of the face and frontal headache. A complete 
palsy of the right oculomotor nerve and an incomplete palsy of the 
right abducens were seen. CT-scan of the brain showed an intrasellar 
tumour with parasellar extension to the right. Treatment with SMS, 100 
\iq s.c, three times a day, resulted in complete resolution of comp-
laints and symptoms within less than 3 wk. A second CT-scan showed 
shrinkage of the tumour. This report suggests an important therapeutic 
role of SMS 201-995 when urgent treatment is required in ophthalmople-
gia due to pituitary GH producing adenomas. 
INTRODUCTION 
Ophthalmoplegia without visual field defects is a rare complication 
of pituitary adenomas nowadays, especially in acromegaly [1]. The first 
treatment is often neurosurgical decompression, although results are 
conflicting. We report an acromegalic patient whose ophthalmoplegia 
completely resolved during treatment with the long-acting somatostatin 
analogue SMS 201-995 (SMS; Sandoz, Basle, Switzerland). This drug, 
which is currently widely used, has been shown to have a long-acting 
inhibitory effect on plasma growth hormone (GH) in patients with acro-
megaly without rebound hypersecretion [2-5]. This paper is the first 
well documented report of such an improvement. 
CASE REPORT 
A 60-yr-old obese woman had a history of arthrosis, nephrolithiasis and 
slight hypertension. Twenty months before admission, acromegaly without 
sellar enlargement or visual field defects was diagnosed. This was con-
firmed by enhanced basal GH levels (11-18 mU/1, RIA) which did not de-
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cline during an oral glucose tolerance test. She has since been treated 
with bromocriptine, 2,5 mg, three times a day. Two months prior to ad­
mission, diabetes mellitus was detected, which was treated with a diet 
and glibenclamide medication. During this period, GH levels during bro­
mocriptine therapy were at a mean level of 20 mU/1. This was considered 
to be due to continuing activity of acromegaly. SMS-therapy or neuro­
surgery were proposed, but she postponed the decision. 
In the 4 wk prior to admission, she noticed a predominantly right-
sided constant hyperaesthesia of the hairy scalp, and frontal headache 
developed. Four days before she was admitted, she also developed pain 
around the right eye, followed the next day by diplopia, dizziness and 
nausea. On admission there were also complaints of paresthaesias predo­
minantly on the right side of the face and the back of the tongue and 
palate, as well as toothache in the right upper jaw, although she was 
edentulous. In addition to bromocriptine 7.5 mg/day and glibenclamide, 
her medication consisted of amiloride 5 mg/day and hydrochlorothiazide 
50 mg/day. 
Physical examination showed no acute distress, but slightly elevated 
blood pressure: RR 160/95 mmHg. There was a nearly total ptosis of the 
right eye and complete palsy of the right oculomotor nerve and an in­
complete palsy of the right abducens. No proptosis was seen. The right 
pupil was dilated and did not react to light either directly or consen-
sually. Corneal sensation was diminished on the right side. Visual 
fields were normal. Laboratory investigation revealed a glucose level 
of 10.7 mmol/1. Further routine blood tests were unremarkable. 
A high resolution CT-scan of the brain showed an intrasellar tumour 
predominantly localised in the right part of the sella with some with 
some bulging to the suprasellar region and slight parasellar extension 
to the right. There was an even distribution of contrast in the pitui­
tary without impressive asymmetrical colouring of the cavernous sinuses 
(Fig.l). 
Therapy was started the day after admission with 100 цд SMS, admi­
nistered subcutaneously three times a day. On day 3 the pain around the 
eye disappeared, followed the next day by amelioration of eye movements 
and decrease of pupil width and ptosis. After 1 wk, ptosis and hyper­
aesthesia had totally disappeared and diplopia was only noticed while 
glancing to the right. On day 19, all complaints and symptoms had been 
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completely resolved. GH levels during treatment decreased to a mean 
value of 4 mU/1, measured 4 h after SMS injection. 
Fig.l High-resolution CT-scan of the pituitary region before 
(A) and after (B) 3 wk of treatment with SMS 201-995. See 
text for further details. 
A second CT-scan, performed three weeks after starting therapy, sho-
wed tumour shrinkage, established by a decline of bulging to the supra-
sellar region. Just a slight parasellar reduction was seen on the right 
side (Fig.l). 
Presently (follow up: seven months) she is still continuing 
SMS-treatment; she remains well and is without symptoms. 
DISCUSSION 
We strongly believe that this patient suffered from eye symptoms due 
to tumour growth, which also explains her rather slowly developing com-
plaints, the development of overt diabetes and the rise of GH levels 
despite bromocriptine therapy. This lack of an acute event together 
with an even distribution of contrast in the pituitary excludes pitui-
tary apoplexy as an explanation. 
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Compared to the frequent shrinkage of prolactinomas treated with 
bromocriptine, this phenomenon has only rarely been described during 
such treatment of acromegaly [6]. However, during SMS-therapy, tumour 
diminution has been reported in 60% of 27 acromegalics [7], while in 
one, relief of ophthalmoplegia was also achieved [4]. This latter pa-
tient had a recurrence after stopping self-administration of the drug 
and improved again after restarting treatment. In our patient, just a 
slight parasellar reduction of the tumour on the right side was demon-
strated by CT-scan 3 wk after starting SMS, but visual improvement has 
previously been shown to precede shrinkage of pituitary adenomas [8]. 
There has recently been a report of visual improvement due to SMS in a 
patient with a thyrotropin-secreting pituitary adenoma without ophthal-
moplegia [9]. No shrinkage of the tumour was demonstrated. One must 
await studies on larger series to find out whether tumour diminution 
occurs regularly during SMS-therapy and whether it will be the therapy 
of choice in acromegaly with mechanical complications of the pituitary 
adenoma. 
In conclusion, this report suggests an important therapeutic role 
for SMS 201-995 in ophthalmoplegia due to pituitary GH producing adeno-
mas. 
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CHAPTER 4.2 
ADDENDUM TO CHAPTER 4.1 

The percentage of acromegalics evincing tumor size reduction during 
treatment with the somatostatin analogue SMS 201-995 (SMS) is not ex­
actly known. A slight decrease in tumor size has been reported in 20-
60% of the patients [1-7], sometimes resulting in amelioration of vi­
sual field defects. Some series, however, fail to show any beneficial 
effect on adenoma size or visual field defects [8,9]. Treatment of 
acromegaly with the dopamine agonist bromocriptine only rarely results 
in tumor shrinkage [10]. 
Preoperative size reduction of GH producing adenomas has been sugges­
ted to be helpful to neurosurgeons in removing the pituitary tumor 
[11]. Spinas describes that, although only one out of five SMS pre-
treated adenomas showed overt reduction in volume, all tumors were very 
soft at surgical exposition and the "tumor tissue usually escaped like 
fluid after incision of the dura" [11]. This suggestion has not yet 
been supported by data from controlled studies. 
The mechanism of action of pituitary size reduction by SMS is un­
known. In vitro experiments have shown that the release of GH by cul­
tures of pituitary tumor cells from acromegalic patients is inhibited 
by SMS, while a decrease of the intracellular GH content of the tumor 
cells of some of the preparations was observed after 4-7 days [12]. 
Shrinkage of GH producing adenomas might therefore be caused by a de­
crease of the content of the individual tumor cells rather than by 
cytotoxic effects. Interference with blood supply to the tumor is an­
other possibility, although so far no pituitary infarctions have been 
reported during long-term treatment with SMS and no vascular impairment 
has been revealed in a tumor of a patient treated with octreotide [13]. 
Support for either theory on the mechanism of action comes from the 
observation that after withdrawal of SMS in most patients GH levels ra­
pidly increase with recurrence of symptoms and signs of acromegaly and 
of pretreatment size of the pituitary tumor [3]. 
Theoretically, with regard to tumor size reduction, continuous sub­
cutaneous infusion of SMS might be superior to intermittent injections 
because of the continuous maximal suppression of GH levels. Continuous 
inhibition of release of GH by the tumor and/or decrease of the intra­
cellular GH content of the tumor cells possibly results in more pro­
nounced shrinkage. One case report showed an impressive shrinkage du­
ring continuous infusion of 600 цд per day for 6 months [14]. However, 
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no controlled studies on tumor size reduction comparing intermittent 
with chronic subcutaneous SMS treatment have been performed so far. 
We conclude that, although preoperative treatment of acromegalic pa­
tients seems promising, the definite place of continuous intermittent 
administration of SMS in reducing pituitary tumor size remains to be 
established. 
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ABSTRACT 
The effects on gallbladder motility of long-term treatment with the 
somatostatin analog SMS 201-995 (SMS) were studied in five patients 
with acromegaly treated for 6 to 32 months with 200-300 цд SMS daily. 
SMS (100 цд) or placebo was injected sc 45 min before a standard break­
fast. Gallbladder volume (ultrasonography), plasma cholecystokinin 
(CCK) and pancreatic polypeptide (PP) were measured until 120 min after 
the meal. 
SMS completely suppressed the postprandial gallbladder contraction, 
despite a blunted, though still statistically significant, increase of 
plasma CCK from 1.6 +0.2 pmol/L to an average of 3.7 + 1.7 pmol/L 
(P<0.01). The postprandial plasma PP peak after placebo was replaced by 
a slight but statistically significant decrease after SMS (P<0.05). A 
statistically significant correlation between the plasma CCK values and 
corresponding gallbladder volumes was seen only after placebo injec­
tion, not in the SMS study. 
We conclude that during long term treatment of acromegalics with SMS an 
injection of 100 цд, sc, completely abolishes gallbladder contraction 
for at least 2 hours after a standard breakfast, despite a blunted, but 
still significant CCK release. The data suggest a decreased sensitivity 
of the gallbladder to endogenous CCK during long term treatment with 
SMS. Careful control of patients with respect to the formation of gall­
stones is recommended. 
INTRODUCTION 
The tetradecapeptide somatostatin (Somatotropin Release Inhibiting Hor­
mone, SRIH) has been demonstrated to inhibit postprandial cholecystoki­
nin (CCK) release and exogenously stimulated gallbladder contraction 
when infused in pharmacological dosages [1-5]. The clinical relevance 
of these observations became clear after the development of the long-
acting somatostatin analogue SMS 201-995 (SMS)[6]. This octapeptide has 
a plasma half-life of 114 min (SRIH, 1-3 min), which enables its use in 
long term treatment of acromegaly and endocrine gastrointestinal tumors 
[6-14]. 
Ill 
Like native somatostatin, a single injection of 25 ug of the analog 
in a short-lasting study in normal volunteers caused almost complete 
abolition of gallbladder contraction, CCK release, and pancreatic poly­
peptide (PP) secretion in response to a Lundh meal [15]. So far, no 
data are available on gallbladder motility during long term treatment 
with SMS. Such data could be of importance because of the supposedly 
high incidence of cholelithiasis in patients with SRIH-producing tumors 
[16] and the role of bile stasis in the development of gallstones [17-
20]. 
The aim of our study was to assess the effects of long term treat­
ment with SMS on postprandial gallbladder contraction in patients with 
acromegaly. 
SUBJECTS AND METHODS 
Five patients with active acromegaly (two men and three women; age, 26-
40 yr; weight, 72-110 kg; mean, 88 kg) participated in the study after 
informed consent was obtained. They had been treated by sc injections 
with SMS for 6-32 months, two or three times daily (see Table 1 for 
patient data). The mean daily dose of SMS was 260 цд, ranging from 200-
300 цд. The protocol was approved by the ethics committee of the Nij­
megen University Hospital. 
On two occasions after an overnight fast the patients during a 15-
min period ingested a standard breakfast consisting of 30 g fat, 30 g 
protein and 70 g carbohydrate. Either 100 цд SMS 201-995 (Sandoz Ltd; 
Basel, Switzerland) or placebo (an equal volume of 0.9% saline) was 
administered sc 45 min before the meal. SMS therapy was withheld for 2 
weeks before the off therapy-saline placebo study to avoid a possible 
carry-over effect of the SMS therapy on the responses obtained in the 
saline placebo study. This saline placebo study was performed to demon­
strate the presence of an adequate contraction of the gallbladder to 
the standard meal in these patients. Administration of the meal was 
started at 0 min. Blood was drawn for CCK and PP measurements at t=-
50, 45, 15, and 0 min before the meal and subsequently at 15-min inter­
vals until 120 min after the meal. Each time a blood sample was drawn, 
gallbladder images were obtained by real-time ultrasonography. 
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Table 1. Patient data 
Patient 
no. 
1 
2 
3 
4 
5 
Age 
(y) 
26 
36 
40 
28 
31 
Sex 
F 
M 
F 
M 
F 
Weight 
(kg) 
78 
110 
90 
89 
72 
Daily Dose 
SMS 201-995 
(мд) 
300 
200 
200 
300 
300 
Duration of 
Treatment 
(months) 
28 
6 
11 
20 
32 
In two patients (no. 2 and 4) gallbladder responses as well as plas­
ma CCK and PP were studied after intraduodenal instillation of a modi­
fied Lundh meal, once after SMS injection, and once after saline place­
bo. For that purpose a one-lumen tube was positioned in the second part 
of the duodenum under fluoroscopic control. The meal, consisting of 30 
g fat (corn oil), 30 g protein (Protein 88, Wander, Uden, The Nether­
lands), 50 g dextrose and 300 ml water (all ingredients well mixed), 
was administered by continuous infusion at a rate of 10 ml/min. The 
further design of the study was similar to that of the oral study. 
Gallbladder volume was calculated by the sum of cylinders method 
using a computerized system, as described previously [21]. The varia­
tion of volume measurements ranged from 6.0 to 22.4%. Plasma CCK was 
measured by a sensitive and specific RIA using antibody T204, which 
binds to all carboxy-terminal CCK peptides containing the sulfated ty­
rosine region [22]. The intraassay variation ranged from 4.6 to 11.5% 
and the interassay variation from 11.3 to 26.1%. Plasma PP was measured 
by RIA as described before [23,24]. The intraassay variation was bet­
ween 4.4 and 7.2% and the interassay variation between 6.8 and 12.1%. 
Basal was defined as the situation at the moment just before admini­
stration of SMS (45 min before the meal), whereas preprandial repre­
sents the moment just before ingestion of the meal (time zero). Inte­
grated gallbladder contraction, plasma CCK and plasma PP were determi­
ned by calculating the area under the curve after subtraction of the 
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preprandial value. Residual gallbladder volume in the individual pa-
tient was defined as the gallbladder volume after maximal contraction. 
Results were expressed as the mean + SEM. statistical analysis was 
performed by the Student t-test for paired data (p), by Friedman two-
way analysis of variance (P)[25] and by testing the means of Spearman's 
rank correlation coefficients (P*). 
RESULTS 
Before injection of SMS or placebo gallbladder volumes were very simi-
lar (24.2 + 5.4 vs. 21.5 + 2.5 cm3 (p>0.70). Ingestion of a standard 
breakfast after placebo induced a highly significant decrease in gall-
bladder volume from a preprandial volume of 21.6 +3.5 cm3 to a mean 
nadir value of 4.4 + 1.2 cm3 at 120 min (P<0.002; Fig.l). 
Fig. 1. 
Gallbladder volume (cm*) — 
40-
30 
30 60 90 120 
time (mm) 
Gallbladder volume in five patients with acromegaly after sc 
injection of 100 mcgr SMS 201-995 or placebo 45 min before a 
standard breakfast. The asterisks indicate statistically sig-
nificant differences between the placebo and SMS studies 
(p<0.005 - p<0.0005). 
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time (rnin) 
Fig. 2 Plasma cholecystokinin (CCK) concentrations in five patients 
with acromegaly after sc injection of 100 mcgr SMS 201-995 or 
placebo 45 min before a standard breakfast. The asterisks indi-
cate statistically significant differences between the placebo 
and SMS studies (p<0.05 - p<0.0005). 
The mean preprandial gallbladder volume after injection of SMS was so-
mewhat higher than the basal value (32.3 + 3.2 cm3 vs. 24.2 +5.4 cm3, 
Fig.l), but this difference was not statistically significant. After 
SMS injection no significant change in postprandial gallbladder volume 
was observed (P>0.10). The gallbladder volume in the SMS study was sig-
nificantly higher than in the placebo study from 15 to 120 min after 
the meal (p<0.005 - p<0.0005; Fig.l). Obviously, the mean residual 
gallbladder volume after placebo was significantly lower than that af-
ter SMS (3.3 + 1.0 cm3 vs. 26.4 + 3.0 cm3, p<0.005). Also, the integra-
ted gallbladder contraction showed a marked difference between the pla-
cebo and SMS study (1437 + 263 cm3.120 min vs. -125 + 194 cm3.120 min, 
p<0.05). 
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Before injection of SMS or placebo, plasma CCK levels were virtually 
identical (2.1 + 0.2 pmol/L vs. 2.2 + 0.2 pmol/L, p>0.70; fig.2). After 
placebo injection the standard breakfast evoked an immediate and sta-
tistically significant increase in the plasma CCK concentration from a 
preprandial value of 2.0 +0.2 pmol/L to 5.2+1.1 pmol/L at 75 min 
(P<0.005; Fig.2). After SMS injection only a gradual but statistically 
significant postprandial increase of plasma CCK was observed, from 1.6 
+ 0.2 pmol/L to a maximum value of 3.7 + 1.7 pmol/L at 120 min 
(P<0.01). Plasma CCK levels after SMS were significantly lower than 
after placebo until 75 min after the meal (p<0.05 - p<0.0005, Fig.2). 
Integrated plasma CCK secretion after SMS was also significantly lower 
than after placebo (133.7 + 60.2 pmol.L-:i.120 min vs. 310.4 + 65.5 
pmol.L-1.^ min, p<0.01). 
Before injection of SMS or placebo plasma PP levels were essentially 
the same (27+3 pmol/L vs. 3 3 + 4 pmol/L, p>0.10; Fig.3). Ingestion of 
the standard breakfast after placebo induced a highly significant and 
fast increase in plasma PP from 31 + 3 pmol/L to a mean maximum level 
Of 195 + 39 pmol/L at 15 min (P<0.005,· Fig.3). After SMS injection no 
postprandial plasma PP elevation was observed. Conversely, a slight but 
statistically significant decrease of plasma PP from a basal value of 
2 7 + 3 pmol/L to a mean nadir of 18 + 2 pmol/L was recorded (P<0.05). 
Plasma PP levels after SMS were significantly lower than after placebo 
throughout the test period (p<0.05-p<0.005; Fig.3). Evidently, integra-
ted plasma PP secretion after placebo was significantly higher than 
after SMS (10410 + 1919 pmol.L-1.^ min vs. -130 + 212 pmol.L-:L.120 
min; p<0.01). 
The inhibitory effects of SMS obtained after intraduodenal instil-
lation of nutrients (patients 2 and 4) were similar to those after the 
oral administration (Table 2). Testing the means of Spearman's rank 
correlation coefficients, a statistically significant correlation bet-
ween the plasma CCK values and corresponding gallbladder volumes was 
found only in the placebo study ,not in the SMS study up to 105 min 
after the meal (0-60 min: rho=-0.60 (P*<0.01) vs. -0.04 (NS); 0-75 min: 
rho=-0.69 (P*<0.01) vs. 0.16 (NS); 0-90 min: rho=-0.50 (P*<0.01) vs-
0.01 (NS); 0-105 min: rho= -0.42 (P*<0.02) vs. -0.17 (NS). 
During the experiments reversible gallbladder sludge was seen in 
only one patient (no.4). No gallstones were noted. 
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Table 2. Inhibitory effects cf SMS 201-995 after oral and intraduodenal instillation cf nu-
trients in two patients with acromegaly 
Gallbladder contraction 
(cm3.120 min) 
AUC CCK1 
(pmcl/L.120 min) 
AUC PP2 
(pmcl/L.120 min) 
Patient no.24 
Saline placebo 
SMS study 
Patient nc.4 
Saline placebo 
SMS study 
Oral study 
1723 
-396 
539 
-224 
I.D.3 
3694 
-475 
923 
-1079 
Oral study 
422 
269 
512 
260 
I.D. 
425 
153 
683 
86 
Oral study 
7463 
-180 
16830 
-668 
I.D. 
7867 
113 
9615 
45 
1
 Integrated plasma cholecystckinin secretion 
2
 Integrated plasma pancreatic polypeptide secretion 
3
 Intraduodenal study 
* See Table 1 for patient data 
Plasma PP(pmol/L) 
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Fig.3 Plasma pancreatic polypeptide (PP) concentrations in five pa-
tients with acromegaly after sc injection of 100 mcgr SMS 
201-995 or placebo 45 min before a standard breakfast. The 
asterisks indicate statistically significant differences be-
tween the placebo and SMS studies (p<0.05 - p<0.005). 
DISCUSSION 
In this study the effects of chronic treatment with a long-acting soma-
tostatin analog on gallbladder contraction, postprandial CCK and pan-
creatic polypeptide secretion were investigated in acromegalic pa-
tients. The study reveals that during chronic treatment with SMS the 
postprandial gallbladder contraction is completely abolished after in-
jection of 100 цд SMS 45 min before an oral meal. These results are 
reminiscent of the findings by Lembcke et al. [15] in an acute study 
with healthy volunteers using 25 цд of SMS and an oral Lundh meal. That 
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dose, however, was far below the dose commonly used in acromegalics. In 
their short lasting studies gallbladder contraction after stimulation 
by the Lundh meal was almost completely abolished by SMS on the sixth 
day of treatment with 25 \ig SMS, sc, twice daily. Apparently, as we 
showed in our study, absence of gallbladder contraction persists during 
chronic treatment of acromegaly with therapeutic doses of the somatos-
tatin analog for months or even years. 
It should be noted that the inhibitory action of SMS on postprandial 
gallbladder contraction was accompanied by a delayed and blunted but 
still statistically significant increase in plasma CCK, which is gene-
rally believed to play a crucial role in gallbladder contraction in 
response to meals of different compositions [26-28]. The slowing down 
of CCK release in our SMS study cannot be attributed to delayed stimu-
lation of the CCK cells in the duodenum due to slower gastric emptying 
after SMS, as in 2 patients the results were essentially the same after 
intraduodenal administration of the nutrients. In contrast to the data 
of Lembcke et al. [15], who demonstrated almost complete suppression of 
postprandial CCK response on the sixth day of administration of the 
lower dose of 25 \ig SMS, sc, twice daily in healthy volunteers, plasma 
CCK release in the acromegalics in the present study was not completely 
inhibited. The cause of this discrepancy in CCK responsiveness is not 
known but it suggests a partial escape of the CCK-producing cells from 
the suppressing action of the somatostatin analog. During chronic 
treatment such a mechanism of adaptation has been suggested in patients 
with gastrointestinal hormone-producing tumors treated with SMS 
[29,30], but the phenomenon has not been recorded in the treatment of 
GH-producing pituitary tumors. The difference in postprandial plasma 
CCK increase between healthy volunteers and acromegalic patients might 
also be due to a lower sensitivity of the CCK-producing cells to the 
inhibitory action of SMS in the latter. 
Despite the statistically significant rise of plasma CCK levels af-
ter the standard breakfast in the SMS study, no gallbladder contraction 
was observed, although the CCK increment required for gallbladder con-
traction in response to exogenous CCK did exceed the threshold of 1.3 
pmol/L previously determined in healthy volunteers [28]. All but one of 
our acromegalic patients (no.l) showed an increase of plasma CCK far 
beyond this level.This suggests a decreased sensitivity of the gall-
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bladder to endogenous CCK during long-term treatment with SMS, at least 
in acromegalics. This is further supported by the absence of a statis-
tically significant direct correlation between plasma CCK levels and 
corresponding gallbladder volumes in the SMS, but not in the placebo, 
study. A direct effect of SMS at the gallbladder level might account 
for this decreased sensitivity to CCK. Possibly, CCK receptors are 
down-regulated directly by the somatostatin analog, although it has 
been demonstrated that the interaction between native somatostatin and 
CCK is of the non-competitive type [4]. In that same study, another 
possibly direct effect of somatostatin on gallbladder motility was an 
observed progressive increase in gallbladder volume in response to in-
creasing doses of the tetradecapeptide suggesting an effect opposite to 
that of CCK [4]. The same tendency was demonstrated in the present stu-
dy with the octapeptide, where the mean preprandial gallbladder volume 
after injection of SMS was somewhat higher than the basal value· though 
this difference lacked statistical significance. The existence of a 
direct effect is further substantiated by the presence of SRIH recep-
tors in the gallbladder [31]. Apart from direct effects, SMS may indi-
rectly change the gallbladder response to an appropriate CCK stimulus 
by interfering with the complex system of gallbladder-stimulating or-
inhibiting hormones. Theoretically, for instance, chronic overstimula-
tion by the SRIH analog might account for high plasma levels of PP, 
which is suggested to be a physiological hormonal inhibitor of gall-
bladder contraction [32-34]. In the present study we demonstrated how-
ever, that after SMS treatment, PP release in response to a meal was 
completely abolished and postprandial plasma PP levels were, in fact, 
reduced to below the basal values. 
Our finding of an impairment of the gallbladder contraction in res-
ponse to the appropriate stimulus during SMS therapy may be of clinical 
relevance. Bile stasis, a risk factor for the development of gall-
stones, during chronic treatment with SMS, was made very plausible by 
our results. Furthermore, SMS therapy may have increased biliary lipid 
concentration, thereby increasing the risk of gallstone formation [35]. 
However, contradictory results on the effects of SRIH on biliary lipid 
composition and bile acid output have been reported [35-37]. Surpris-
ingly, reversible sludge was found in only one out of five patients. No 
gallstones were noted in 11 other acromegalic patients intermittently 
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treated with SMS (follow-up 6-40 months, our personal data). The cause 
of absence of gallstone formation in our acromegalics is not clear, but 
it may be related to a different bile composition in these patients or 
to partial or total recurrence of postprandial gallbladder emptying 
several hours after one of the injections, abolishing bile stasis as a 
risk factor. This explanation is supported by the rather short half-
life of the SRIH analog (114 min after sc injection). Theoretically the 
incidence of gallstones is expected to be higher in the group of pa-
tients treated with continuous sc infusion of SMS, which resembles the 
situation in somatostatinoma patients where the incidence of gallstones 
is about 40% [16]. Although the occurrence of cholelithiasis has been 
reported several times during chronic therapy with SMS [10,38], the 
incidence seems less than one would expect in view of the results of 
the present study. Careful ultrasonographic control of patients on long 
term SMS treatment with regard to the appearance of biliary sludge and 
gallstones is recommended to interpret correctly possible abdominal 
symptoms occurring in these patients. 
In conclusion, during long term treatment of acromegalics with SMS 
postprandial gallbladder contraction is completely abolished for at 
least 2 h after injection of 100 \ig of the SRIH analog despite a blun-
ted but still significant CCK release. The data suggest a decreased 
sensitivity of the gallbladder to endogenous CCK during long-term 
treatment with SMS at least in acromegaly. Careful control of patients 
treated with SMS with respect to gallstone formation is recommended, in 
particular for those treated with continuous sc administration of SMS. 
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ABSTRACT 
Long-term treatment with the somatostatin analogue SMS 201-995 (SMS) 
might impair exocrine pancreatic function, secretion of cholecystokinin 
(CCK) and pancreatic polypeptide (PP), and pancreatic size. In 5 acro­
megalics on chronic treatment with SMS, we investigated postprandial 6 
h urinary excretion of p-aminobenzoic acid (PABA) and p-aminosalicylic 
acid (PAS) after sc injection of 100 ug SMS or placebo and after inges­
tion of 2 mmol пВТ-РАВА and 2 mmol PAS. 
In the acromegalics urinary PABA/PAS ratio, reflecting exocrine 
pancreatic function, after SMS was similar to that after placebo 
(p>0.10) and higher than in healthy volunteers (n=8, p=0.05). The ini­
tial inhibition of plasma CCK secretion by SMS was cancelled during 
the third hour after the meal, whereas PP release remained completely 
abolished. No pancreatic hypotrophy (ultrasonography) was recorded in 7 
acromegalics as compared to 14 healthy volunteers. 
It is concluded that, despite a blunted CCK release, long-term 
treatment with SMS 201-995 neither induces pancreatic hypotrophy nor 
deterioration of postprandial exocrine pancreatic function in patients 
with acromegaly. 
INTRODUCTION 
Infusion of synthetic soinatostatin-14 (Somatotropin Release Inhibiting 
Hormone, SRIH) both at physiological and supraphysiological rates pro­
vokes brief inhibitory effects on exocrine pancreatic function in labo­
ratory animals and man [1-14]. This inhibitory action of somatostatin 
became clinically relevant since the development of the long-acting 
somatostatin analogue SMS 201-995 (SMS)[15]. This octapeptide has a 
plasma half-life of 113 min (SRIH: 1-3 min)[16], which makes possible 
its use in long-term treatment of acromegaly and endocrine gastrointes­
tinal tumours [17-24]. 
Like native somatostatin, the analogue causes inhibition of exocrine 
pancreatic secretion in short-lasting studies [25-32]. In acromegaly 
during treatment with the analogue for more than 4 weeks, steatorrhoea 
and acute weight loss have been recorded in 3 out of 54 patients [33]. 
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So far, no data are available obtained by a more accurate, non-invasive 
method of evaluating exocrine pancreatic function during long-term 
treatment with SMS. Such data could be of importance because of the 
allegedly high incidence of steatorrhoea in patients with somatostatin 
producing tumours [34]. In order to delineate this effect we investiga­
ted patients with acromegaly on long-term treatment with SMS using the 
para-aminobenzoic acid (ΡΆΒΑ) test combined with para-aminosalicylic 
acid (PAS) to compensate for abnormalities in PABA absorption and meta­
bolism [35]. In addition basal and postprandial plasma cholecystokinin 
(CCK), the major hormonal stimulus of pancreatic exocrine secretion, 
and pancreatic polypeptide (PP), a putative hormonal inhibitor of pan­
creatic exocrine secretion, were measured to assess their roles in 
postprandial exocrine pancreatic function during SMS treatment. 
Apart from exerting a stimulatory action on exocrine pancreatic 
secretion, CCK is also tenown to stimulate pancreatic growth [36]. The­
refore, to determine whether chronic SMS treatment induced pancreatic 
hypotrophy caused by a putative withdrawal of this trophic CCK effect, 
we also investigated pancreatic size during chronic treatment with SMS. 
PATIENTS AND METHODS 
Seven patients with active acromegaly (age 26-40 years; 2 men, 5 women) 
participated in the study after giving informed consent. All had been 
treated with subcutaneous (sc) injections of SMS, 100 \iq 2-3 times 
daily for 3-32 months (see Table 1 for patient data). None had gastro­
intestinal abnormalities that might interfere with the PABA test and 
all body weights were stable. The protocol was approved by the ethics 
committee of Nijmegen University Hospital. 
After an overnight fast, five patients (nos 1-5) on two occasions, 
on and off SMS, during a 15 min period ingested a standard breakfast 
consisting of 30 g fat, 30 g protein and 70 g carbohydrates (one slice 
of white bread, 5 g margarine, 50 g cheese, 200 g yoghurt with 50 g 
dextrose, one soft-boiled egg and 150 ml tea) together with 2 mmol N-
benzoyl-L-tyrosyl-p-aminobenzoic acid (BT-PABA; Fluka AG, Buchs, Swit­
zerland) and 2 mmol p-aminosalicylic acid (PAS; Sigma, St Louis; Mis­
souri, U.S.A.). Water intake was encouraged during the test to guaran-
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tee adequate urine production. After the consumption of the substrate, 
urine was collected for б hours. To check the absence of substances 
that might interfere with the analysis, pre-load urine samples were 
also analysed. 
Either 100 цд SMS 201-995 (Sandoz Ltd; Basle, Switzerland) or placebo 
(an equal volume of saline 0.9%) was administered sc 45 min before the 
meal. SMS therapy was withheld for two weeks prior to the "off therapy-
saline placebo" study to avoid a possible "carry over" effect of the 
SMS therapy on the responses obtained in the saline placebo study. This 
saline placebo study was performed to demonstrate the presence of an 
adequate pancreatic exocrine secretion in these patients. Blood was 
drawn for CCK and PP measurements at t= -50, -45, -15, and 0 min and 
subsequently at 15 min intervals until 180 min after starting the meal 
(t=0 min). 
Eight healthy volunteers (age 18-25 years; 4 men, 4 women) served as 
controls for the PABA test without prior injection of SMS or placebo. 
After alkaline hydrolysis of the PABA and PAS metabolites in the urine, 
analysis was undertaken by high performance liquid chromatography 
(HPLC) as described before [35,37]. The amounts of PABA and PAS recove­
red from the 6 h urine sample were expressed as percentages of the PABA 
equivalents administered orally as BT-PABA and of the quantity of PAS 
administered orally. The PABA/PAS ratio, i.e., the ratio of the per­
centages of recovered PABA and PAS was calculated. 
Plasma CCK was measured by a sensitive and specific radioimmunoassay 
using antibody T204, which binds to all biologically active carboxy-
terminal CCK peptides containing the sulfated tyrosine region [38]. The 
intra-assay variation ranged from 4.6 to 11.5%. Plasma PP was measured 
by radioimmunoassay as described before [39,40]. The intra-assay varia­
tion was between 4.4 and 7.2%. To avoid interassay variation, all sam­
ples from one individual were measured in the same assay. "Basal" was 
defined as the situation at the moment just before administration of 
SMS (t=-45 min), whereas "preprandial" represents the moment just be­
fore ingestion of the meal (t=0). Integrated plasma CCK and plasma PP 
were determined by calculating the area under the plasma concentration-
time curve after subtraction of the preprandial value. 
Pancreatic size was determined by real-time ultrasonography in 
seven acromegalic patients (nos 1-7) during chronic SMS treatment as 
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well as after a two week washout period and in 14 healthy volunteers 
(age 18-39 yrs; 8 men, 6 women) The maximum anteroposterior diameter of 
the head and the body of the pancreas were measured on a transver­
se/oblique scan, using the upper abdominal blood vessels as landmarks 
[41]. These diameters were expressed in cm per m 2 body surface. 
Results were expressed as the mean + standard error of the mean 
(SEW). Statistical analysis was performed by Student's t-test for pai­
red or unpaired data (ρ), and by Friedman's two-way analysis of varia­
nce (P)[42]. All tests were two-tailed. 
Table 1. Patient Data 
Patient 
no. 
1 
2 
3 
4 
5 
6 
7 
Age 
(years) 
26 
36 
40 
28 
31 
31 
28 
Sex 
F 
M 
F 
M 
F 
F 
F 
Daily Dose 
SMS 201-
300 
200 
200 
300 
300 
200 
300 
-995 
Duration of 
Treatment 
(months) 
28 
6 
11 
20 
32 
17 
3 
RESULTS 
In the placebo study the mean 6 h urinary PABA excretion tended to be 
higher in the acromegalics than in the control subjects (72+9% vs 57 
+ 2%, 0.05<p<0.10; Table 2, Fig.l), whereas the excretion of PAS was 
virtually similar (44 + 5% vs 50 + 4%, p>0.10; Table 2, Fig.2). The 
mean PABA/PAS ratio was significantly higher in the acromegalics than 
in the controls (1.62 + 0.05 vs 1.23 + 0.09, p<0.01; Table 2, Fig.3). 
After the SMS injection PABA and PAS excretion decreased in all pa­
tients as compared with the placebo value, but the decline was not 
statistically significant (Table 2, Figures 1 and 2.). After SMS the PAS 
excretion was lower than in the controls (32+4% vs 50 + 4%, p<0.005), 
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Table 2. Urinary Excretion of PABA and PAS 
Healthy 
Acromegalics (n=5) volunteers {n=8) 
SMS Placebo 
PABA-excretion (%) 4 9 + 8 ( * ) 7 2 + 9 5 7 + 2 ( * ) 
PAS-excretion (%) 32 + 4 (*#) 4 4 + 5 5 0 + 4 
PABA/PAS ratio 1.54 + 0.11 (*) 1.62 + 0.05 1.23 + 0.09 (») 
* 0.05<p<0.10 vs placebo (acromegalics) 
# p<0.005 vs healthy volunteers 
ψ p<0.01 vs placebo (acromegalics) 
φ p=0.05 vs healthy volunteers 
whereas urinary PABA excretion was virtually the same (49 + 8% vs 57 + 
2%, p>0.10). Nevertheless, compared with the placebo study the PABA/PAS 
ratio in the acromegalics remained essentially unchanged after SMS and 
still was significantly higher than in the control subjects (1.54 + 
0.11 vs 1.23 + 0.09, p=0.05; Table 2, Fig.3). 
Before injection of SMS or placebo plasma CCK levels were virtually 
identical (2.1 + 0.2 pnol l"1 vs 2.2 + 0.2 pnol l"1, p>0.70). After 
placebo injection the standard breakfast evoked an immediate and sta­
tistically significant increase of plasma CCK concentration from a 
preprandial value of 2.0 + 0.2 pnol l - 1 to 5.2 + 1.1 pnol l - 1 at 75 min 
(P<0.005). After SMS injection only a gradual but statistically sig­
nificant postprandial increase of plasma CCK was observed, from 1.6 + 
0.2 pnol l - 1 to a maximum value of 4.1 + 1.3 pnol l - 1 at 180 min 
(P<0.01). Plasma CCK levels were significantly lower after SMS than 
after placebo upto 75 min after the meal (p<0.05 - p<0.0005). The in­
tegrated plasma CCK secretion during the first 60 min postprandial 
interval was significantly lower after SMS than after placebo (38.6 + 
24.6 vs 152.7 + 45.9 pnol 1-Ix60 min, p<0.01; fig.4), but in the 2nd 
and 3rd intervals this difference was no longer statistically signifi­
cant. 
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Fig.l Postprandial six h urinary PABA excretion after intake of 2 mmol 
BT-PABA in five patients with acromegaly after sc injection of 
100 mcgr SMS 201-995 or placebo, and in eight healthy volun­
teers. 
PAS excretion (V.) 
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Fig.2 Postprandial six h urinary PAS excretion after intake of 2 mmol 
PAS in five patients with acromegaly after sc injection of 100 
mcgr SMS 201-995 or placebo, and in eight healthy volunteers. 
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Fig.3 Ratio of postprandial six h urinary excretion of PABA and PAS 
after intake of 2 mmol PABA and 2 mmol PAS in five patients with 
acromegaly after sc injection of 100 mcgr SMS 201-995 or place-
bo, and in eight healthy volunteers. 
Before injection of SMS or placebo plasma PP levels were essentially 
the same ( 2 7 + 3 pmol l-1 vs 33 + 4 pmol 1 1, p>0.10). Ingestion of the 
standard breakfast after placebo induced a fast and highly significant 
increase in plasma PP from 3 1 + 3 pmol l-1 to a mean maximum level of 
195 + 39 pmol l - 1 at 15 min (P<0.005). This increase was completely 
abolished after SMS injection. Obviously plasma PP levels (p<0.05-
0.005) and also the integrated PP secretion (p<0.05-0.01) after SMS 
were significantly lower than after placebo throughout the test period 
(Fig.5). 
No clinical signs of steatorrhoea or excessive weight loss were noted 
in any of the patients. 
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Fig.4 Hourly integrated plasma cholecystokinin (CCK) concentrations in 
five patients with acromegaly after sc injection of 100 mcgr 
SMS 201-995 or placebo 45 min before a standard breakfast. 
Table 3. Pancreatic Size 
Acromegalics (n=7) Healthy volunteers (n=14) 
off SMS on SMS 
Head1 1.48 + 0.09 (*) 1.39+0.12 
Body1 1.02 + 0.09 (#*) 0.69 + 0.02 
1.20 + 0.07 
0.69 + 0.02 
1
 diameter (centimeters per m 2 body surface + SEM) 
* p<0.05 vs healthy volunteers 
# p<0.05 vs acromegalics "on SMS" 
ψ p<0.0005 vs healthy volunteers 
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Fig. 5. Hourly integrated plasma pancreatic polypeptide (PP) concen­
trations in five patients with acromegaly after sc injection 
of 100 mcgr SMS 201-995 or placebo 45 min before a standard 
breakfast. 
During chronic SMS treatment diameters of the head and body of the 
pancreas in acromegalics were found to be not statistically signifi­
cantly different from those in healthy volunteers (p>0.10, Table 3). 
Remarkably, after stopping SMS therapy for two weeks, pancreatic body 
diameter was significantly larger than during SMS treatment (p<0.05), 
while no significant changes occurred in the pancreatic head diameter 
(p>0.10). After withdrawal of SMS therapy both the pancreatic head and 
body diameters were significantly larger compared with those in the 
healthy volunteers (p<0.05 and p<0.0005). 
135 
DISCUSSION 
In this study the effects of chronic treatment with a long-acting soma­
tostatin analogue on exocrine pancreatic function, postprandial CCK 
and PP secretion were investigated in acromegalic patients. The study 
reveals that long-term treatment with SMS does not result in serious 
deterioration of exocrine pancreatic function as assessed from the 
PABA/PAS ratio after injection of 100 цд SMS 45 min before an oral 
meal. It has to be noted, however, that though the PABA/PAS ratio re­
mained virtually unchanged, both urinary PABA and PAS excretion de­
creased in most acromegalic patients to values slightly (PABA) or even 
significantly (PAS) lower than in the control subjects. These data 
suggest that SMS interferes with the intestinal absorption of both 
compounds, but leaves the PABA/PAS ratio, as a measure of exocrine 
pancreatic function, unaffected. 
The finding of an unchanged PABA/PAS ratio after SMS in the acrome­
galic patients of this study is in apparent contrast to the trypsin and 
lipase data of Lembcke et al. in their acute and short-lasting studies 
in healthy volunteers [26]. These investigators demonstrated almost 
complete suppression of duodenal trypsin and lipase output in response 
to endogenous stimulation by a Lundh meal after 6 days of pretreatment 
with SMS 25 цд sc twice daily. Mean faecal fat excretion increased from 
7.6 to 19.2 g in 24 hrs, but tended to decrease with time. In an acute 
study Köhler et al. [25] noted a reduction of secretin-cerulein stimu-
lated trypsin and amylase output during infusion of 27, 80, 240 and 720 
ng kg-1 hr-1 SMS. The degree of inhibition, however, was not related to 
the dose of SMS. The data of the present study however are in agreement 
with a clinical study conducted in 54 patients with acromegaly receiv-
ing daily doses of 100-300 цд SMS for more than 4 weeks. In that study 
clinical or significant steatorrhoea and weight loss were noted in only 
3 of the 54 patients [33]. Measurement of daily total stool fat in 14 
patients in this same series admittedly showed an average increase from 
2.6 to 6 g, but no clinical evidence of malabsorption. These apparently 
contradictory results in healthy volunteers and patients with acromega­
ly may be explained first by the fact that reduced enzyme output does 
not necessarily lead to clinically relevant symptoms of malabsorption. 
In addition the monitoring period used by Lembcke et al in the Lundh-
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test (2 hrs) is limited compared with the 6-hour period we used in 
evaluating exocrine pancreatic secretion. Furthermore, in the healthy 
volunteers treated with SMS, also faecal fat excretion decreased and 
CCK stimulated pancreatic enzyme secretion increased with time [26]. An 
alternative explanation might be an increased reserve capacity of ex-
ocrine pancreatic function in acromegalics. The striking finding of a 
significantly higher PABA/PAS ratio in acromegalics as compared with 
the healthy volunteers supports this hypothesis. 
So far we have no explanation of the apparently more effective ex-
ocrine pancreatic function in these patients except their pancreatome-
galy (vide infra). Similar data confirming or refuting these data in 
man are not available. In pigs, however, intensive treatment with por-
cine somatotropin does not result in a better digestive potency (Van 
Weerden, personal communication). 
To evaluate the role of CCK and PP in postprandial exocrine pancrea-
tic enzyme secretion, both peptides were also measured during this 
study. CCK has been suggested to play a pivotal role in regulating the 
intestinal phase of pancreatic secretion and stimulating pancreatic 
enzyme production, while PP in physiologic doses is known to inhibit 
pancreatic enzyme secretion in man [43,44]. In dogs, however, a physio-
logical role of PP as an endocrine inhibitor of postprandial pancreatic 
enzyme secretion recently has been questioned, because immunoneutrali-
zation of PP did not enhance pancreatic exocrine secretion [40]. The 
slowing down of CCK release in the acromegalic patients in our chronic 
SMS study contrasts with the data of Lembcke et al in healthy volun-
teers [26]. They found almost complete suppression of postprandial CCK 
release on the 6th day of SMS administration. As discussed earlier the 
causes of this discrepancy might be a partial escape of the CCK-produc-
ing cells from the suppressing action of the somatostatin analogue or a 
lower sensitivity of the CCK producing cells to the inhibitory action 
of SMS in acromegalics compared with healthy volunteers [45]. Neverthe-
less residual CCK release after SMS in the acromegalics of the present 
study probably prevented suppression of the exocrine pancreatic func-
tion, as reflected by the unaltered PABA/PAS ratio. Furthermore this 
residual CCK release by its trophic action may have prevented pancrea-
tic hypotrophy that is to be expected theoretically. A rather surpris-
ing finding was the increase in pancreatic body size after withdrawal 
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of SMS therapy for only two weeks. Theoretically this may be the result 
of the resumption of full CCK release, restoration of splanchnic blood 
flow [46], and recurrence of excessive growth hormone secretion by the 
pituitary tumour resulting in high plasma concentrations of growth 
factors, such as Insulin-Like Growth Factor I. 
Meal-induced PP release has been reported to be abolished after a 
single dose or short course of SMS. In the present study we demonstra-
ted that during chronic SMS treatment also the plasma PP peak in res-
ponse to a meal is still completely abolished at least for the three 
hour study period. Probably the inhibitory effect of SMS on peak PP in 
concert with the incomplete and only transient suppression of CCK both 
guaranteed a virtually normal exocrine pancreatic enzyme function as 
demonstrated by the unchanged mean PABA/PAS ratio. This supposition is 
further supported by the finding in healthy volunteers that pancreatic 
enzyme secretion in response to exogenous CCK was inhibited to only 35 
to 50% of control values on the seventh day of SMS treatment [26], a 
level known to be sufficient for adequate absorption of nutrients. 
In conclusion: this study illustrates that long-term intermittent 
treatment with SMS 201-995 in patients with acromegaly does not seri-
ously deteriorate postprandial exocrine pancreatic secretion, probably 
due to the fact that postprandial CCK secretion is inhibited only in-
completely and transiently. Despite suggestions of pancreatic involu-
tion during chronic SMS therapy, this treatment does not result in 
pancreatic hypotrophy. The higher PABA/PAS ratios in acromegalics as 
compared with healthy volunteers, especially in the placebo period, 
suggest increased digestive capacity due to pancreatic enzymes in these 
patients, probably resulting from their pancreatomegaly. 
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SUMMARY 
The primary approach in the treatment of acromegaly is surgical, wher-
eas radiation therapy should be considered adjunctive. Long-term medi-
cal therapy is recommended when surgery has not been successful while 
awaiting the effect of radiotherapy. Treatment with the dopamine ago-
nist bromocriptine leads to reduction of plasma growth hormone (GH) to 
the normal range in only about 30% of the patients, rather frequently 
causing gastrointestinal side-effects. Infusion of Somatotropin Release 
Inhibiting Hormone (SRIH, somatostatin) in acromegalic patients also 
results in lowering of GH secretion. However, chronic treatment with 
this natural tetradecapeptide is not practical due to its short half-
life (1-3 min) urging continuous infusion therapy, and the rebound GH 
secretion after termination of SRIH administration. One of its analo-
gues, the octapeptide octreotide (SMS 201-995, SMS, SandostatinB), has 
proved to be longer acting (6-8 h) and more active and selective in GH 
suppression than SRIH, while lacking excessive rebound GH secretion. It 
has been used now in acromegalic patients administering the drug sub-
cutaneously, either intermittent or continuous, resulting in normal 
nadir GH levels in about 70% of the patients during long-term treat-
ment. SMS has been generally well tolerated. Rarely occurring side ef-
fects during long-term treatment are steatorrhea, diabetes mellitus and 
probably cholelithiasis. No consensus exists how to determine a "cure" 
biochemically, especially in the case of intermittent subcutaneous 
administration of SMS, when highly variable GH levels interfere with a 
correct estimation of efficacy. Beside clinical features, measurement 
of IGF-I levels has been suggested for monitoring of this treatment. 
Controlled comparative studies with bromocriptine on chronic treatment 
with both drugs are still lacking, but the efficacy of octreotide seems 
superior. Apart from acromegaly, octreotide has been successfully used 
in the symptomatic and palliative treatment of endocrine tumours of the 
gastrointestinal system. Furthermore, promising results have been ob-
tained in the dumping syndrome, high output secretory diarrhea, intes-
tinal and pancreatic fistulas, several solid tumours and postprandial 
hypotension. 
The recommended dosage schedules for intermittent subcutaneous therapy 
with SMS in acromegaly vary widely. In chapter 2 the results of a sin-
gle-dose response study in five patients with acromegaly are described, 
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using doses of 25, 50, 100, 200 and 400 pg SMS as well as placebo in­
jection. Plasma GH of two patients did not normalize after any of the 
injections, but nadir GH overall gradually decreased as doses were in­
creased from 25 to 400 цд. The 400 ug dose was superior with regard to 
the duration of plasma GH suppression to below 5 цд/1 or 25% of the 
basal GH level, the mean GH as a percentage of the basal level over the 
first 4 and 8 hours. The postprandial integrated insulin secretion du­
ring the first three hours after injection of SMS was significantly 
lower after 50, 100 and 400 мд than after the placebo injection. Within 
the limitations of this admittedly small numbered single-dose response 
study we concluded that injection of 400 ug yields the best results 
with regard to suppression of GH secretion, while the 50, 100 and 200 
цд doses are superior to 25 цд, but do not differ from each other. 
In chapter 3 studies on the efficacy of long-term treatment with octre­
otide in acromegaly are described. Eight out of twelve patients with 
active acromegaly (chapter 3.1) initially treated with 50 цд SMS twice 
daily and after two weeks with 100 \ig b.i.d. achieved normal plasma GH 
levels. Basal glucose levels were significantly lower at the 28th day 
of treatment. The postprandial rise of insulin levels was reversed by 
SMS, leading to a more pronounced rise of glucose after the test meal, 
whereas the postprandial secretion of glucagon was also reversed by 
octreotide. The TRH-induced TSH response was significantly blunted. 
Paradoxical GH responses to TRH disappeared in 7 out of 8 patients. 
Paradoxical GH responses to GnEH however persisted in the 4 patients 
who showed this phenomenon before treatment, whereas paradoxical GH 
responses after glucose loading disappeared. The GH response after GHRH 
administration was strongly suppressed by octreotide. 
Chapter 3.2 reports on the results of GH secretion studies in 8 acrome­
galics before and during treatment with 100 цд of the octapeptide ana­
logue sc twice daily, evaluating GH day profiles and suppressibility of 
GH secretion after oral glucose tolerance tests (OGTT). This test has 
been shown to be a reliable tool in the assessment of GH secretion af­
ter pituitary surgery and in the assessment of bromocriptine therapy. 
Normalization of GH secretion, estimated by OGTT was only observed in 
the three patients who showed a decrease in plasma GH to less than 2 
цд/1 after SMS injection and who had the lowest mean plasma GH levels 
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during the day and the largest percentual decline of mean plasma GH 
levels. We concluded that true normalization of GH secretion during SMS 
201-995 therapy only occurs in a subset of patients. The data illu­
strate that the generally held cut-off value of 5 \ig/l between normal 
and abnormal plasma GH has to be reconsidered in the case of chronic 
intermittent subcutaneous therapy with SMS 201-995. 
Structurally different from native somatostatin, the octapeptide octre­
otide is at potential risk of inducing antibody formation, thereby im­
pairing the effect of octreotide treatment. We therefore investigated 
serum samples of thirteen patients (chapter 3.3) with active acromegaly 
on long-term subcutaneous treatment with SMS (1-36 months), twelve 
hours after the injection of their regular evening doses. No specific 
binding was detected using both serum charcoal adsorption (adsorption 
of free SMS) and polyethylene glycol precipitation (precipitation of 
IgG complexes). This was compatible with the fact that there had been 
no need to gradually increase the SMS dose in our patients to maintain 
the same therapeutic effect for as long as five years. The results 
strongly suggests that clinically relevant endogenous antibody forma­
tion does not occur during long-term sc treatment with octreotide in 
acromegaly. 
In chapter 4 we report on an acromegalic patient whose ophthalmoplegia, 
caused by parasellar extension of the pituitary tumour, completely re­
solved during treatment with octreotide. Treatment with the SRIH-analo-
gue, 100 цд sc thrice daily, resulted in complete resolution of com­
plaints and symptoms in less than 3 weeks. A CT-scan showed shrinkage 
of the pituitary adenoma. 
During treatment with SMS a slight decrease in tumour size has been 
reported in 20-60% of the patients. Possibly, pre-operative treatment 
with octreotide might be helpful to neurosurgeons in removing the tu­
mour. With this regard theoretically continuous sc infusion of SMS 
might be superior to intermittent administration. Sofar however, no 
controlled studies comparing intermittent and continuous infusion with 
regard to tumour size reduction have been performed. Therefore, the 
definite place of these two treatment modalities in reducing pituitary 
tumour size remains to be established. 
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Native somatostatin has been demonstrated to inhibit postprandial cho-
lecystokinin (CCK) release, exogenously stimulated gallbladder contrac­
tion, postprandial pancreatic polypeptide (PP) secretion and exocrine 
pancreatic function. Chapter 5.1 reports on five patients with acrome­
galy, treated for 6-32 months with 200-300 μ SMS daily. Compared with 
placebo, octreotide completely suppressed postprandial PP secretion and 
gallbladder contraction for at least 2 hours after a standard break­
fast, despite blunted but still significant CCK release. The data sug­
gest a decreased sensitivity of the gallbladder to endogenous CCK du­
ring long-term treatment with SMS. Careful control of patients with 
respect to the formation of gallstones was recommended. 
In chapter 5.2 exocrine pancreatic function and pancreatic size of five 
patients with acromegaly on chronic treatment with octreotide are de­
scribed by measuring 6 hour urinary excretion of p-aminobenzoic acid 
(PABA) and p-aminosalicylic acid (PAS) after sc injection of 100 \ig SMS 
or placebo and after ingestion of equimolar amounts of nBT-PABA and 
PAS. In the acromegalics urinary PABA/PAS ratio, reflecting exocrine 
pancreatic function, was significantly higher than in healthy volun­
teers, but after SMS therapy similar to that after placebo. No pancrea­
tic hypotrophy - which theoretically might occur due to CCK suppression 
- was recorded in 7 acromegalics after long-term treatment with octre­
otide. 
In conclusion, octreotide seems to be a useful tool in the medical 
treatment of acromegaly. It effectively lowers plasma GH levels in a-
cute studies, subcutaneous doses of 50, 100 and 200 цд being superior 
to 25 μg. During long-term treatment it still is effective in suppres­
sing plasma GH secretion without eliciting endogenous antibody forma­
tion. True normalization of GH secretion as assessed by oral glucose 
tolerance tests, however, seems to occur only in the small group of 
acromegalics reaching the nadir of 2 цд/1 or less after injection of 
SMS. Nevertheless, the paradoxical responses to TRH - not to GnEH - are 
abolished in most patients. Octreotide is able to reduce pituitary tu­
mour size even resulting in relief of ophthalmoplegia. Finally, octreo­
tide abolishes postprandial PP secretion and gallbladder contraction 
during long-term treatment in acromegaly despite a blunted but still 
significant CCK release. Exocrine pancreatic function after long-term 
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SMS treatment, however, is similar to that after placebo and remains 
superior to that in healthy volunteers. 
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SAMENVATTING 
Chirurgie is de eerste keus bij de behandeling van acromegalie, waarna 
radiotherapie zonodig aanvullend gebruikt kan worden. Langdurige medi-
camenteuze behandeling wordt aanbevolen indien chirurgie niet het ge-
wenste resultaat oplevert en het effect van radiotherapie moet worden 
afgewacht. Behandeling met de dopamine-agonist, bromocriptine, normali-
seert de spiegel van groeihormoon (GH) in bloed bij ongeveer 30% van de 
patiënten en veroorzaakt vrij vaaJc gastrointestinale bijwerkingen. In-
fusie van Somatotropin Release Inhibiting Hormone (SRIH, somatostatine) 
vermindert eveneens de GH secretie bij acromegalen. Chronische behande-
ling met dit natuurlijk voorkomende tetradecapeptide is echter niet 
praktisch vanwege de korte halfwaardetijd (1-3 min) die continue infu-
sie noodzakelijk zou maken, en door de "rebound" GH secretie na stop-
zetten van de toediening van SRIH. Een van zijn analoga, het octapepti-
de octreotide (SMS 201-995, SMS, SandostatinR), werkt langer (6-8 uur) 
en is actiever en selectiever met betrekking tot onderdrukking van GH 
dan SRIH, terwijl overmatige "rebound" GH-secretie na stoppen ervan 
niet optreedt. Het wordt gebruikt bij patiënten met acromegalie in de 
vorm van subcutane toediening, intermitterend of continu. Bij ongeveer 
70% van de patiënten worden tijdens chronische behandeling normale GH-
dalwaarden bereikt. SMS wordt over het algemeen goed verdragen. Zelden 
voorkomende bijwerkingen tijdens langdurige behandeling zijn steator-
rhee, diabetes mellitus en mogelijk galstenen. 
Er bestaat geen consensus over het biochemisch vaststellen van een "ge-
nezing" door SMS, vooral niet tijdens intermitterende subcutane toedie-
ning, waarbij sterk variabele GH spiegels een juiste inschatting van 
het effect bemoeilijken. Naast het scoren van klinische parameters is 
ook de bepaling van spiegels van "insulin-like growth factor" (IGF-I) 
voorgesteld om deze behandeling te reguleren. Gecontroleerde vergelij-
kende studies met het effect van bromocriptine tijdens chronische be-
handeling ontbreken nog steeds, maar het effect van octreotide lijkt 
beter. Afgezien van acromegalie is octreotide met succes toegepast als 
symptomatische en palliatieve behandeling van endocriene tumoren van 
het maag-darm kanaal. Veelbelovende resultaten zijn geboekt bij het 
"dumping"-syndroom, volumineuze secretoire diarree, dunne darm- en pan 
creasfistels, verschillende solide tumoren en bij postprandiale hypo-
tens ie. 
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De aanbevolen doseringsscíiemata voor de intermitterende subcutane be-
handeling met SMS bij acromegalie lopen ver uiteen. In hoofdstuk 2 wor-
den de resultaten beschreven van een onderzoek naar het effect van één 
dosis bij vijf patiënten met acromegalie. Doseringen van 25, 50, 100, 
200 en 400 pg SMS alsmede een placebo werden onderhuids toegediend. Bij 
twee patiënten normaliseerde de GH-spiegel in het bloed niet, maar nam 
de GH-dalwaarde af bij verhoging van de dosis van 25 naar 400 \iq. De 
400 цд dosis was het meest effectief met betrekking tot de duur van de 
onderdrukking van het plasma-GH onder de 5 цд/1 of tot minder dan 25% 
van de basale GH-spiegel, en met betrekking tot de gemiddelde GH-con-
centratie als percentage van het basale niveau gedurende de eerste 4 en 
8 uur. Na een proefmaaltijd was de geïntegreerde insuline-secretie ge-
durende de eerste 3 uur na injectie van SMS significant lager na 50, 
100 en 400 цд dan na een placebo- injectie. Hoewel deze studie slechts 
een klein aantal patiënten betrof, concludeerden wij dat injectie van 
400 pg de beste resultaten geeft met betrekking tot de onderdrukking 
van GH-secretie, terwijl de 50, 100 en 200 цд doses beter zijn dan 25 
цд, maar onderling niet van elkaar verschilden. 
In hoofdstuk 3 wordt de effectiviteit van langdurige behandeling met 
octreotide bij acromegalie beschreven. Bij acht van twaalf patiënten 
met actieve acromegalie (hoofdstuk 3.1), die aanvankelijk behandeld 
werden met 50 цд en na twee weken met 100 цд SMS twee maal daags sub-
cutaan normaliseerden de plasma GH-spiegels. De basale glucose concen­
traties waren op de achtentwintigste dag van de behandeling significant 
lager. Na een proefmaaltijd trad er geen stijging van insuline-spiegels 
meer op of daalden deze zelfs, met als gevolg een meer uitgesproken 
stijging van de glucose-waarden in het bloed. Ook de secretie van glu­
cagon daalde tijdens octreotide. De door TRH geïnduceerde stijging van 
TSH-spiegels werd significant minder. Het "paradoxale" GH-antwoord op 
TRH verdween bij 7 van 8 patiënten, de GH-nresponsn op GnRH echter 
bleef bestaan bij de 4 patiënten die dit fenomeen vóór de behandeling 
vertoonden. Het paradoxale antwoord van GH na glucose-belasting ver-
dween tijdens SMS. Het antwoord van GH op toediening van GHRH werd door 
octreotide vrijwel geheel onderdrukt. 
In hoofdstuk 3.2 worden de resultaten van onderzoek naar de GH-secretie 
bij 8 acromegalen vóór en tijdens behandeling met 100 цд SMS, twee maal 
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daags subcutaan, gerapporteerd. Geëvalueerd werden de waarde van het 
profiel van GH-concentraties over de dag en de onderdrukbaarheid van de 
GH-secretie na orale glucose belasting. Dit laatste onderzoek heeft 
zijn waarde bewezen bij het vaststellen van de GH-secretie na hypofyse-
chirurgie en tijdens behandeling met bromocriptine. Normalisering van 
de GH secretie — beoordeeld aan de hand van de orale glucose-toleran-
tie test — werd alleen waargenomen bij die drie patiënten, die na SMS-
injectie een daling van de plasma-GH spiegels tot minder dan 2 pg/l 
lieten zien, die de laagste gemiddelde plasma GH spiegels over de dag 
hadden en de grootste procentuele afname van de gemiddelde plasma GH-
concentraties lieten zien. Wij concludeerden hieruit, dat tijdens SMS 
echte normalisering van GH secretie slechts bij een deel van de pati-
ënten optreedt. De gegevens illustreren verder dat de over het algemeen 
aangehouden grenswaarde van 5 цд/1 tussen een normale en een abnormale 
plasma GH-spiegel bij chronische intermitterende subcutane behandeling 
met SMS 201-995 aan herwaardering toe is. 
Daar het octreotide structureel verschilt van het natuurlijk voorkomen­
de somatostatine, zou het potentieel aanleiding kunnen geven tot vor­
ming van antilichamen, waardoor het effect van octreotide-behandeling 
teloor zou kunnen gaan. Daarom onderzochten we, twaalf uur na injectie 
van de gebruikelijke avond-dosis, serum-monsters van dertien patiënten 
met actieve acromegalie (hoofdstuk 3.3) die langdurig met SMS waren 
behandeld. Er werd geen specifieke binding vastgesteld, noch met de 
"charcoal adsorptie-techniek" (adsorptie van vrij SMS) noch na precipi-
tatie van IgG uil serum met behulp van polyethyleen glycol. Dit is in 
overeenstemming met het gegeven dat er gedurende een jarenlange periode 
geen noodzaak bestond om bij onze patiënten de SMS-dosis geleidelijk op 
te hogen om hetzelfde therapeutische effect te handhaven. De resultaten 
suggereren derhalve dat er over een jarenlange periode tijdens inter-
mitterende injecties met octreotide bij acromegalie geen, klinisch re-
levante, endogene anti lichaamvorming optreedt. 
In hoofdstuk 4 wordt de ziektegeschiedenis van een patiënte met acrome-
galie beschreven wier Ophthalmoplegie - veroorzaakt door een parasel-
laire uitbreiding van de hypofysetumor - volledig verdween tijdens be-
handeling met octreotide. Behandeling met de SRIH-analoog (100 \ig drie 
maal daags, subcutaan) leidde tot volledig verdwijnen van klachten en 
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Symptomen in minder dan drie weken. CT-scans toonden verkleining van 
het hypofyse-adenoom. 
In 20 tot 60% van de patiënten leidt behandeling met SMS tot een door-
gaans geringe afname van de tumorgrootte, zo werd gerapporteerd. Moge-
lijkerwijze zou een pre-operatieve behandeling met octreotide de neuro-
chirurg van dienst kunnen zijn voor een optimaal resultaat van zijn 
werk. In dit opzicht zou continue subcutane infusie van SMS theoretisch 
effectiever kunnen zijn dan intermitterende toediening. Tot nu toe zijn 
er nog geen gecontroleerde studies uitgevoerd die het effect van inter-
mitterende en continue infusie op de grootte van de tumor met elkaar 
vergelijken. De definitieve plaats van deze twee behandelingswijzen 
staat daarom nog niet vast. 
Uit literatuurgegevens blijkt dat het natuurlijk voorkomende somatosta-
tine het vrijkomen van cholecystokinine (CCK) na een proefmaaltijd, de 
exogeen gestimuleerde galblaascontractie, de "postprandiale" secretie 
van pancreas polypeptide (PP) en de exocriene panereasfunctie remt. 
Hoofdstuk 5.1 beschrijft vijf patiënten met acromegalie, die gedurende 
6-32 maanden dagelijks behandeld waren met 200-300 \ig SMS. Octreotide 
bleek zowel de postprandiale PP-secretie als de galblaascontractie vol-
ledig te onderdrukken gedurende tenminste twee uur na een 
proefmaaltijd, ondanks een weliswaar verminderde, maar toch nog aan-
zienlijke afgifte van CCK. De gegevens suggereren een verminderde ge-
voeligheid van de galblaas voor endogeen CCK tijdens langdurige behan-
deling met SMS. Daarom lijkt het zinvol patiënten tijdens behandeling 
met SMS zorgvuldig te controleren met betrekking tot de vorming van 
galstenen. 
In hoofdstuk 5.2 zijn gegevens over de exocriene panereasfunctie en de 
pancreasgrootte van patiënten met acromegalie, die chronisch behandeld 
werden met octreotide, bijeengezet. De 6 uurs urine-uitscheiding van p-
aminobenzoeen zuur (ΡΑΒΆ) en p-aminosalicylzuur (PAS) werd gemeten na 
subcutane injectie van 100 \ig SMS of placebo en na inname van equi-
molaire hoeveelheden n-butyl-tyrosyl-PABA en PAS. Bij de acromegalen 
was de urine PABA/PAS ratio, die de exocriene pancreasfunctie weerspie­
gelt, significant hoger dan bij gezonde vrijwilligers, maar na SMS-the-
rapie vergelijkbaar met die na placebo- toediening. Verkleining van de 
pancreas door hypotrofie, die op theoretische gronden zou kunnen optre-
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den door onderdrukking van CCK tijdens langdurige behandeling met oc­
treotide, werd bij bij geen van de zeven onderzochte acromegalen waar­
genomen. 
Samenvattend wordt bevestigd dat octreotide een bruikbaar middel is om 
acromegalie medicamenteus te behandelen. In acute studies verlaagt SMS 
het plasma-GH, waarbij subcutane doses van 50, 100 en 200 pg effectie­
ver zijn dan 25 цд. Tijdens langdurige behandeling blijken geen antili­
chamen te worden gevormd en blijft de werkzaamheid onveranderd. Echter, 
normalisering van de GH-secretie — zoals te meten met een orale gluco­
se tolerantie-test — lijkt alleen op te treden in de kleine groep 
acromegalen die na een SMS-injectie een dalwaarde voor groeihormoon 
bereiken van 2 цд/1 of minder. De paradoxale antwoorden van GH op TRH-
maar niet op GnRH - verdwenen overigens bij de meeste patiënten. Oc-
treotide is in staat om de hypofysetumor bij acromegalen te verkleinen, 
hetgeen zelfs kan leiden tot opheffen van een begeleidende Oph-
thalmoplegie, zoals wij éénmaal duidelijk waarnamen. Tenslotte doet 
octreotide tijdens langdurige behandeling bij patiënten met acromegalie 
de postprandiale PP-secretie en galblaascontractie te niet, ondanks een 
verminderde, maar nog aanzienlijke afgifte van CCK. De exocriene pan-
creasfunctie na langdurige behandeling met SMS bleek overigens na een 
eenmalige toediening van SMS of een placebo niet te verschillen. Opmer-
kelijk is nog dat deze orgaanfunctie bij acromegalen beter ontwikkeld 
is dan bij gezonde vrijwilligers zowel vóór als na toediening van het 
octapeptide. 
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deerde hij van 1973 tot 1976 Psychologie aan de Katholieke Universiteit 
te Nijmegen. In 1975 begon hij in diezelfde plaats met de studie Ge­
neeskunde, resulterend in het doctoraalexamen in 1980 en het artsexamen 
in 1982. 
Aansluitend was hij tot 1985 als internist in opleiding werkzaam op 
de afdeling Interne Geneeskunde in het Groot Ζiekengasthuis te »s-Her-
togenbosch (opleiders: Dr. J.B. Lips en Dr. J.L.J. Jansen), waarna de 
opleiding afgerond werd in de Universiteitskliniek voor Inwendige Ziek­
ten van het Sint Radboudziekenhuis te Nijmegen (opleider: Prof.Dr. A. 
van 't Laar). Inschrijving in het register van erkende medische specia­
listen vond plaats in september 1987. 
In het begin van datzelfde jaar werd op de afdeling Endocriene 
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van het College ter Beoordeling van Geneesmiddelen. 
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J.H.E. Custers en Dr. E.W. van der Hoek. 
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STELLINGEN 
behorende bij het proefschrift 
OCTREOTIDE IN THE TREATMENT OF ACROMEGALY 
P.A. van Liessum 
1. Langdurige intermitterende subcutane toediening van octreotide bij 
acromegalie is een effectieve groeihormoon-verlagende therapie. 
Dit proefschrift 
2. Volledige normalisering van de groeihormoonsecretie tijdens behan-
deling met octreotide bij acromegalie -- zoals gemeten met een 
orale glucose tolerantie test -- treedt slechts bij een deel van 
de patiënten op. 
Dit proefschrift 
3. Tijdens jarenlange intermitterende subcutane toediening van octre-
otide aan patiënten met acromegalie vindt zeer waarschijnlijk geen 
klinisch relevante antilichaamvorming plaats. 
Dit proefschrift 
4. Gedurende langdurige behandeling van acromegalie met octreotide 
wordt na een injectie met dit octapeptide de galblaascontractie na 
een maaltijd volledig teniet gedaan ondanks een aanzienlijke af-
gifte van cholecystokinine (CCK). Dit suggereert een verminderde 
gevoeligheid van de galblaas voor dit hormoon. 
Dit proefschrift 
5. Bij patiënten met acromegalie wordt de exocriene pancreasfunctie 
na een maaltijd niet in ernstige mate verstoord door langdurige 
intermitterende toediening van octreotide. 
Dit proefschrift 
6. Alcoholinjectie in de hypofyse kan een bruikbaar alternatief zijn 
bij de behandeling van ondraaglijke pijn bij de patiënt met kan-
ker. 
P.A. van Liessum et al. Ned Tijdschr Geneeskd 1986;130:631-4 
7. De 5-hydroxytryptamine-3 antagonist ondansetron is een effectief 
anti-emeticum zowel bij cisplatinum bevattende als bij niet-cis-
platinum bevattende chemotherapie. 
P.H.M. De Mulder, P.A. van Liessum. Eigen waarneming 
Θ. Voor het ontstaan van de door interleukine-2 geïnduceerde hypo-
thyreoidie zijn LAK-cellen waarschijnlijk niet noodzakelijk. 
P.A. van Liessum et al. Lancet 1989;I:224 
9. De directe bijdrage aan het welbevinden van onze patiënten door 
een proefschrift in de geneeskunde moet, zelfs als het klinisch 
onderzoek betreft, over het algemeen als zeer beperkt worden in-
geschat. 
(Zie) dit proefschrift 
10. Waar "perifere" ziekenhuizen zich voor medische adviezen vaak wen-
den tot de alma mater, verdient het voor de directie van een aca-
demisch ziekenhuis aanbeveling dit eenrichtingsverkeer op te hef-
fen als het gaat om organisatie, de daarmee samenhangende effi-
ciëntie en het kweken van een "wij-gevoel". 
Eigen waarneming 
11. Leren zweefvliegen tijdens de afronding van een proefschrift en 
het overnemen van een internistenpraktijk getuigt van een grove 
onderschatting van de benodigde tijd en de moeilijkheidsgraad van 
deze fascinerende sport. 
12. De voltooiing van een dissertatie impliceert geenszins een hoog 
waarheidsgehalte van stellingen die niet aan het onderwerp van 
onderzoek gerelateerd zijn. 
Zie deze stellingen 
Januari 1990 

